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INTRODUCTION 
Amyotrophic lateral sclerosis is a devastating disorder with inexorable progressive 
course. It is the third major neurodegenerative illnesses apart from Parkinson’s disease 
and Alzheimer’s disease.  
The very first report characteristic of ALS was noted by Jean- Marie Charcot (1825-1893) 
in 1874, and named this fatal syndrome based upon what he found. He described the 
clinical and pathological manifestations of “la sclérose latérale amyotrophique,” a 
disorder of muscle wasting (amyotrophy) and sclerosis of the anterior and lateral 
corticospinal tracts (1). 
Several other names have been given to this condition including Charcot disease, motor 
neuron disease, and “Lou Gehrig disease” in memory of the popular baseball player who 
was diagnosed with ALS in 1939 (2). Lou Gehrig was a lead baseball player in New 
York. His diagnosis with this disease led to his retirement in his career in 1939. He 
subsequently died in 1941, which brought a lot of attention to this disease. 
Amyotrophic lateral sclerosis (ALS) is a disease of motor neurons. It is a progressive 
degeneration of the motor system at all levels - from the cortex to the anterior horn of the 
spinal cord (3). Thus clinical features comprise of only motor system findings. The 
course of the disorder is relentlessly progressive, with at least 50% of patients dying 
within 3 years of onset (3).  
ALS can be sporadic (90%) or familial (5-10%). The familial cases usually follow 
Mendelian pattern of inheritance. Till date approximately 13 genes and loci of major 
effect have been identified (2, 3). Mutations in SOD1 account for 20% of familial ALS (6) 
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and 5% of apparently sporadic disease. There are only a few case reports from India (7) 
and the familial ALS, although very much existent, is largely an unexplored area. 
ALS affects people worldwide but, an exact incidence of this disease is not yet known 
(8). The incidence of sporadic amyotrophic lateral sclerosis is said to be uniform 
throughout the world. Women have a lower incidence of disease (2.4 per 100 000 
person-years) than do men (3 per 100 000 person years), although the incidence 
between men and women is almost the same in familial disease. 
The overall lifetime risk of ALS is 1:350 for men and 1:400 for women. Peak age at onset 
is 47–52 years for familial disease and 58–63 years for sporadic disease. Incidence 
decreases rapidly after 80 years of age (7). There are no major studies from India to give 
information on exact prevalence and incidence of the disease in India. Reviewing the 
case series data and anecdotal reports (9), it can be generalized that males are more 
often affected than females. The disease affects people in the productive phase of their 
life.  
The hallmark of ALS is the presence of UMN (upper motor neuron) and LMN (lower 
motor neuron) features. The patients can present with:  
o bulbar-onset disease – seen in 25% of patients or  
o limb-onset disease – seen in about 70% of cases, or  
o initial trunk or respiratory involvement - 5%, subsequently spreading to 
involve other  regions (10), (11) 
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Atypical ways of presentation can include cramps and fasciculations without muscle 
weakness, weight loss - a poor prognostic sign, emotional labiality, and frontal lobe-type 
cognitive dysfunction (12). 
Older age of onset, early respiratory muscle involvement, and bulbar-onset variant are 
associated with poor prognosis and reduced survival, whereas limb-onset disease, 
younger age of onset, and longer time between first symptom and diagnosis are 
predictors of prolonged survival (13). Some ALS phenotypes tend to have a better 
prognosis - predominantly LMN forms like flail-limb variant ALS and progressive 
muscular atrophy (10, 11). Additionally, patients with primary lateral sclerosis (PLS) and 
predominant UMN phenotypes also progress more slowly as compared than to patients 
with classic ALS (10, 12). Studying these various phenotypes and distinguishing them 
from the typical ALS phenotype has implications not only for clinical trials of disease-
modifying agents but also has a bearing on survival, prognosis, quality of life and day-to-
day care of individual patients.  
Most patients with ALS have mild cognitive impairment with subtle executive deficits, and 
5% have a clinical subtype of fronto-temporal dementia (FTD). Many authors have since 
suggested that ALS and fronto-temporal dementia form a clinical and pathological 
spectrum. Cognitive deficits initially has a subtle appearance and more than often are 
overlooked in view of more prominent motor dysfunction, but with appropriate 
neuropsychological assessment and cognitive battery, 20–50% of patients with ALS fulfill 
the criteria for probable or definite FTD (16). The most common deficits involve executive 
function (17), either affecting language or personality. The cognitive profile mostly 
resembles that of behavioral-variant FTD. The  clinical implications are conspicuous with 
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problems in judgment, impulsivity, and a general deterioration in undertaking routine 
daily tasks (18), Cognitive, and particularly executive dysfunction, can also adversely 
affect patient compliance with treatment and decision-making abilities. 
One third of patients with amyotrophic lateral sclerosis report sensory symptoms and 
sural sensory amplitudes are also reduced a third of them. Pathologic evidence of 
sensory nerve pathology was present in 91% of patients who underwent sural nerve 
biopsy (19). The electrophysiological and pathologic findings indicate a pattern of axonal 
loss that predominantly affects large-caliber myelinated fibers. ALS associated with 
generalized sensory system abnormalities may be consistent with degeneration of motor 
neurons and dorsal root ganglion cells (19). 
ALS was traditionally believed to spare cognitive, sensory, and affective functions, but as 
described above, it is now firmly established that it is not a pure motor syndrome, but 
more of a multisystem disorder. Most of this knowledge comes from western data. But 
the genetics, demography, social circumstances, education background, occupation, 
food habits, toxin exposure etc in Indian subpopulation bears hardly any resemblance to 
European or North American population. The data so obtained from literature can be 
extrapolated to our set-up but it can hardly be representative of our patients. In such 
scenario, the need of time is a longitudinal analysis of ALS patients in India.   
There are various methods to assess progression of disease status in ALS. MUNE 
(Motor Unit Number Estimation), Axon Excitability, Transcranial Magnetic Stimulation 
(TMS) and clinical rating scales are few of the common once. Among all, the clinical 
examination and rating scales like Norris Score, Appel Scale, and ALSFRS-R – still gives 
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the best subjective and objective assessment over a verified duration of time. ALSFRS-R 
has a high reliability, internal consistency, validity, and responsiveness to change. The 
patients who had a low score on the scale succumb earlier than those with a higher 
scores, and the change in the scale also closely parallels other measures such as 
muscle strength, muscle mass, and brainstem abnormalities (20). 
The standard of care provided is also as heterogeneous as the disease itself. Wide 
variety of rehabilitation and end-of-life care practices are prevalent in India. The other 
unique fact considering Indian scenario is the use of Indigenous and native medications, 
some of which contains toxic substances like heavy metals contributing to rapid 
progression of the disease. Also, these potentially toxic substances could also add on to 
the on-going pathology leading to clinical findings of Myokymia which have not been well 
characterized in literature. These also have an effect on cognition (21). 
The cognitive involvement can be studied and objectively documented by 
multidisciplinary higher mental function tests. LMN degeneration is also well 
characterized by bed-side motor system examination as well as electromyography/nerve 
conduction tests. But the challenge is to objectively demonstrate and quantify UMN 
pathology which often starts in the primary motor and premotor cortex. It is often difficult 
to decide whether the UMN is involved. Both neurophysiological and neuroimaging 
techniques have been used to evaluate UMN pathology.  
Diffusion tensor imaging (DTI) is a relatively new method in structural neuroimaging. It 
estimates the orientation of fibers in white matter on the basis of the diffusion 
characteristics of water. Diffusivity is generally higher in directions along fiber tracts than 
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perpendicular to them (22). The directionality of diffusion can be quantified by the 
fractional anisotropy index. Fractional anisotropy (FA) values range from 0 (no directional 
dependence of diffusion coefficients) to 1 (diffusion along a single direction). Changes in 
tissue structure (in this case degeneration of the corticospinal fibers) can lead to a 
modification of the degree of directionality, which can be detected by diffusion tensor 
MRI. Therefore, in degenerated white matter tracts of patients with ALS one would 
expect to find changes in the anisotropy of diffusion in comparison with healthy subjects 
(23). 
The heterogeneity in presentations of ALS (24) are thus crucial to the understanding and 
development of measures of disease progression (25). The identification and 
conceptualization of specific phenotypes has often, indirect but vital implications for 
patients particularly, with regards to prognosis and survival. In a resource crunch country 
like ours, it is even more important to know exactly the pattern of onset, spread and 
progression of the disease so that management options can be individualized. It will also 
aid in optimal utilization of resources with higher yield and economic precision. Thus a 
proper study of natural history of ALS in Indian subpopulation is must along with an in-
depth insight into the multisystem nature of the disease. This was one of the crucial 
factors that motivated us to plan this study. 
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AIM AND OBJECTIVES  
 
 
Aim:  
 
To study the natural history, multisystem nature and spectrum of cognitive dysfunction in 
sporadic Amyotrophic Lateral Sclerosis along with objective assessment of Upper Motor 
Neuron (UMN) involvement utilizing diffusion tensor MRI (DTI). 
 
Objectives:  
 
A. Retrospective Part: 
 
1. To study and document the pattern of onset, spread and rate of progression of 
Sporadic ALS. 
2. To study the spectrum of motor and extra-motor manifestations of Sporadic ALS. 
3. To evaluate and analyze the outcome, factors affecting prognosis, effect of 
therapeutic intervention. 
 
B. Prospective Part: 
4. To assess spectrum of cognitive & behavioral dysfunction in sporadic adult onset 
ALS utilizing Cognitive Batteries and rating scales – PGI Memory Scale 
(P.G.I.M.S.), NIMHANS Battery, Frontal Assessment Battery (FAB), and 
Addenbrooke’s Cognitive Examination (ACE-R). 
5. To compare the DTI indices of patients with ALS with that of normative data. 
6. To correlate DTI indices and cognitive dysfunction scores.  
7. To correlate DTI indices and disease severity in amyotrophic lateral sclerosis 
using functional rating scale – revised (ALSFRS - R)  
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REVIEW OF LITERATURE  
“A-myo-trophy” is the term derived from Greek meaning “no-muscle-nourishment.”  
“Lateral” refers to the location of the corticospinal tract (upper motor neuron) in the spinal 
cord. Hardening or scarring of the nerves and tracts due to degeneration is referred to as 
“sclerosis”.  
Amyotrophic lateral sclerosis is a rare neurodegenerative disease which causes loss of 
upper and lower motor neurons. The motor neurons are lost from the spinal cord, brain 
stem and from the cerebral cortex. This then results in progressive wasting and paralysis 
of voluntary muscles. It is the most progressive form of motor neuron disease and 
causes respiratory insufficiency and death within three to five years of illness (26). 
Types of Motor Neuron Diseases: 
MND is phenotypically heterogeneous, encompassing progressive muscular atrophy (a 
purely lower motor neuron disorder), primary lateral sclerosis (an exclusively upper 
motor neuron disorder), ALS (which combines both upper and lower motor neuron 
features), as well as progressive bulbar palsy, a segmentally predominant form of the 
disease. 
Classical motor neuron disease seen in India is similar to the western population; 
however the onset is earlier by about a decade and patients below the age group of 30 
years is quite high (27, 28).  
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Two subtypes have been described in India.  
1. Single limb involvement also called as "juvenile muscular atrophy of upper extremity", 
monomelic amyotrophy", "wasted leg syndrome" and "benign focal amyotrophy"  
2. Madras pattern of motor neuron disease which was first described by 
Meenakshisundaram & Jagannathan K from South India in 1970.  
The madras pattern of motor neuron disease has an earlier onset (between the ages of 
10 to 30 years) with predominantly male involvement. It usually has a benign course and 
absence of family history. There is usually gradual asymmetric onset of involvement of 
the limbs with wasting. Involvement of the lower cranial nerve nuclei was described. 
Sensorineural hearing loss has been described has the hallmark of Madras Motor 
Neuron Disease (MMND). The other features include involvement of the lower cranial 
nerves – seventh, ninth and twelfth with involvement of the facial and bulbar muscles.  
There is a variant of MMND called as the Madras Motor Neuron Disease Variant 
(MMNDV) in which patients have optic atrophy. A few cases of familial MMND (FMMND) 
have also been described with mode of inheritance being autosomal recessive (29,30, 
31,32). 
Epidemiologically it can be classified into sporadic (90%) and familial forms (10%). In the 
familial group mutations in SOD1 (encodes for superoxide dismutase-1: SOD1) gene are 
found in one fifth of familial ALS cases, mutations in the RNA-processing genes TDP-43 
(TAR DNA Binding protein), and FUS (encodes fusion in sarcoma) are also found in one 
tenth of the cases (10, 9). Between 5% and 10% of ALS is familial - familial ALS (FALS) 
(33). 
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When the onset of the illness is less than 25 years of age the term Juvenile onset ALS 
(jALS) is used. Most of these cases are autosomal recessive. Gene mutations may 
cause autosomal dominant inheritance. 
The World Federation of Neurology Research Group on Neuromuscular Disorders has 
classified ALS as a disorder of motor neurons of undetermined etiology, and several 
variants are known (34). It is essential to know that ALS is a progressive dynamic 
disorder. Some cases present with the classic combination of UMN and LMN signs, but 
others may have UMN onset, LMN onset, bulbar onset, or dyspnea at onset and only 
later develop signs of involvement of the other parts of the motor system. The mean 
duration from onset to death is about 3 years, but around 1 in 5 patients survive to 5 
years, and 1 in 10 patients survive to 10 years (35). 
 
Causes 
There are no specific environmental, physical, or occupational factors that can be 
associated with absolute certainty to an increased risk of ALS. Possible factors include 
chronic exposure to electromagnetic fields, high physical (sports) activity, high intake of 
glutamate in diet, environmental toxins, and a history of service in the Persian Gulf 
War.(36) Smoking is an independent risk factor for sporadic ALS, with a higher risk for 
those who have smoked for many years (37),(38).  Several environmental trace 
elements like Selenium, iron, aluminum, copper, manganese, zinc, cadmium, and lead 
have been postulated as causative agents for ALS, but there is no conclusive evidence 
that any one of these plays a vital part in ALS pathogenesis (39). 
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A recent study in Indian population showed that rural livings, smoking, insecticides, and 
pesticides exposures, electrical injury are “associated factors” in development 
amyotrophic lateral sclerosis (9). 
Clinical Features: 
The hallmarks of ALS pathology are the degeneration and loss of motor neurons. Both 
UMN and LMN cell loss occurs. UMN cell loss occurs in the motor cortex (Betz cells from 
Brodmann area 4) and axonal loss in corticospinal tracts (CST). LMN loss occurs in the 
brainstem and spinal cord. Extramotor pathology includes involvement of the fronto-
temporal cortex, thalamus, hippocampus, dorsal columns, spinocerebellar tracts, and 
substantia nigra (40). 
The typical clinical picture in ALS is that of a patient with a progressive motor 
deterioration manifesting with both UMN and LMN symptoms and signs. The classic 
pattern is that the muscle weakness in ALS begins in a focal area, first spreading to con-
tiguous muscles in the same region before involvement of another region. But not all 
patients present with this classical pattern. Upper limb Onset is more common than the 
lower extremities (classic, spinal ALS), but in approximately 25% of patients, weakness 
begins in bulbar-innervated muscles (bulbar-onset ALS). On rare occasions (1% or 2% 
of patients, more often male), the weakness starts in the respiratory muscles (dyspnea or 
respiratory-onset) (41). Various presentations can be there including pseudopolyneuritic 
or flail leg presentation (42),  monomelic presentation(27), 43), Mills hemiplegic variant, 
flail arm or flail person in the barrel variant.(44). The flail arm variant is also is known as 
the brachial amyotrophic diplegia or the Vulpian-Bernhardt syndrome. In this condition 
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there is weakness involving predominantly the upper limbs. To understand these 
different variants is very important because the natural history, prognosis and survival 
are different in each of these. And based only on these accurate facts, one can plan 
management and rehabilitation tailored to each phenotype, and ultimately to each 
individual. 
As the disease advances, motor function is progressively impaired, and activities of daily 
living (e.g., self-hygiene, bathing, dressing, toileting, and walking, feeding, and verbal 
communication) become difficult. Accordingly, a patient’s quality of life progressively 
deteriorates.(45) 
As dysphagia worsens, muscle weakness is accelerated by reduced caloric intake (46). 
Aspiration of liquids, secretions, and food becomes a risk. Weight loss is often rapidly 
progressive; this is not simply due to poor caloric intake but represents ALS cachexia 
(47). Sleep disturbances in the form of increased awakenings from hypopnea and 
hypoxia are common in ALS and contribute to daytime sleepiness, morning headaches, 
and fatigue. As respiratory difficulty worsens, orthopnea sets in because of worsening 
diaphragmatic weakness and thus compensate by using multiple pillows (48). 
 
Extra-motor Features 
Cognitive impairment is present in many patients with ALS, but on a spectrum from 
apparently normal to a frank FTD (Fronto-temporal Dementia)(49). These observations 
support the idea that ALS is not a pure disorder of motor neurons, but rather a disorder 
that mainly affects motor neurons, with the potential to involve other nonmotor systems 
(40). One needs to be cautious while assessing patients with apparently normal 
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cognition because the deficits may be  subtle requiring specific assessments of 
personality, behavior, verbal fluency, visual attention, and verbal reasoning (50). 
Dysarthria may hide language disturbances (especially anomia). With appropriate tests, 
cognitive deficits may be diagnosed in about 50% of patients with ALS, but the full 
(Neary) criteria for diagnosis of FTD are met only in about 20% of cases (51, 52). In 
India, the social circumstances are such that many of these cognitive features are 
labeled as part of aging or of premorbid personality. It’s very difficult to find families 
coming up with symptoms of cognitive involvement when they bring their family member 
for evaluation of ALS. There is a paucity of Indian literature on cognitive profile of ALS 
patients in India.  
It is extremely rare to see are extrapyramidal dysfunction, abnormal sphincter control, 
eye movement abnormalities, and autonomic disturbances. Approximately 5% of patients 
with ALS show signs of extrapyramidal dysfunction, usually retropulsions during 
attempted ambulation (44).  Autonomic dysregulation is part of degenerative process in 
ALS. There’s considerable decline in sweat secretion (about 20- 40%) over a six month 
period. Overall, the pattern seen in few of the cases is an abnormal sympathetic activity 
with hyperhidrosis in early ALS and as the disease progresses, a reduction in sweat 
production. (53) One of many phenotypes of SOD1-associated ALS has showed 
involvement of the autonomic nuclei in the medulla and spinal cord by a neuropathologic 
study. (54) 
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The ongoing research in the field and thorough epidemiological studies, these 
abnormalities are being documented in more number of patients. There have been 
patients who are kept on mechanical ventilation to prolong life and eye movement 
abnormalities have been documented. 
There are anecdotal reports on sensory involvement in patients with ALS, with clinical, 
electrophysiologic, and pathologic evidence of sensory nerve pathology (19). This 
suggests that the typical ALS phenotype is perhaps broader than previously recognized 
and includes abnormalities of peripheral sensory nerves. Their presence emphasizes the 
point that the motor neuron diseases, although named after the predominant system 
affected, are characterized by pathology that extends beyond involvement of upper and 
lower motor neuronal systems. This recognition may have implications for the way in 
which we conceptualize these diseases and impact our efforts to investigate and 
understand their basic biology and pathophysiology. 
 
Natural History - Onset & Progression 
A linear decline in motor functions is observed once the motor weakness is evident. The 
pattern of disease spread was thought to be predictable. When onset is in one arm, 
spread is often first to the contralateral side, then the ipsilateral leg, the contralateral leg, 
and finally the bulbar region. Onset in the leg often follows the same pattern, with final 
involvement of the bulbar region. Bulbar-onset ALS tends to spread to the hands first, 
with spread to thoracic myotomes, and then the legs. Overall, the pattern suggests that 
rostral-caudal involvement is faster than caudal-rostral spread. During the course of the 
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disease, transitory improvement, plateaus, or sudden worsening can occur, but 
spontaneous improvement, is exceedingly rare.  
The onset and spreading pattern was looked in detail by F. Kimura et al (55). They 
studied 150 patients of ALS. Onset was in the upper limbs in 33%, lower limbs in 35% 
and bulbar in 21%. Overall median survival time was 32 months and mean duration from 
FS-FE (first symptom to first examination) was 14.3 months. Survival was significantly 
shorter with bulbar onset (26 months) than with upper limb onset (33 months) or lower 
limb onset (32 months). A female predominance with older disease onset was seen in 
patients with bulbar onset. The Fist Symptom-Second Symptom (FS-SS) time interval is 
an important predictor of survival. The faster the subsequent region/myotome gets 
affected, the shorter is the survival. But survival was not linked to any particular 
combination of FS-SS, but only to the interval of FS-SS. Early manifestation of bulbar 
symptoms within 1 year was also an important predictor of shorter survival. The spread 
to the contiguous or skip area depends on the onset. When the illness starts with the 
lower limbs, 83% of cases were followed by upper limb symptoms, 3% by respiratory 
symptoms and 14% by bulbar symptoms. When the course began with bulbar 
symptoms, 71% of cases were followed by upper limb symptoms, 29% by lower limb 
symptoms and 0% by respiratory symptoms. When the course began with upper limb 
symptoms, 64% of cases were caudally followed by lower limb symptoms, 5% by 
respiratory symptoms and 32% were rostrally followed by bulbar symptoms. No patient 
with bulbar onset skipped directly to respiratory symptoms without upper limb 
involvement. This knowledge about the pattern of onset and the anatomical direction of 
spread may provide valuable prognostic insights. 
24 
 
Poor Prognostic factors 
The proven poor prognostic factors in ALS are older age at onset and bulbar-onset 
pattern (57). Other important poor prognostic factors include shorter interval between 
onset and clinical diagnosis (a more aggressive onset), rapid progression rate, low body 
mass index, FTD-ALS presentation, dyspnea at onset, and rapid rate of decline in pul-
monary function.(58)(59) Those who have low-amplitude CMAPs in the setting of normal 
sensory potentials (the “generalized low motor-normal sensory pattern”) as revealed by 
nerve conduction studies appear to have a poor prognosis. 
Investigations:  EMG 
Investigations are necessary to exclude other possibilities although the diagnosis of 
clinically definite ALS can sometimes be established on the history and clinical 
examination alone. The electrodiagnostic investigation is an essential tool in the 
evaluation of ALS and its variants. It serves as an extension to the clinical examination 
and is particularly useful in determining the presence or extent of LMN disease. But none 
of the EDX findings are specific for ALS, although they can strongly support the 
diagnosis. Disease monitoring can be done by repeated investigations at intervals. 
Sensory nerve conduction studies are characteristically normal (60).  
In classical cases, nerve conduction studies provide only a little supportive evidence for 
the diagnosis. The sensory nerve action potentials (SNAPs) are normal and there is 
reduction in compound muscle action potentials (CAMPs) amplitude, reflective of the 
motor axonal loss from the death of the anterior horn cells.  The motor nerve conduction 
velocities and distal latencies can be delayed due to the loss of motor axons. Sensory 
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nerve conduction velocities and distal latencies should be normal. There should be no 
evidence of motor conduction block but exceptions are always present (61, 62). 
The EMG examination characteristically reveals a combination of acute (positive sharp 
waves and fibrillation potentials) and chronic (reduced neurogenic firing pattern with 
evidence of increased amplitude and duration, polyphasic motor unit potentials) changes 
in a distribution that does not concur with any single root or peripheral nerve distribution. 
Fasciculation potentials are common and typically of complex morphology; their absence 
should push us to investigate for another disease (60). The recent Awaji-shima criteria 
for the neurophysiological diagnosis of suspected ALS stresses the importance of 
fasciculation potentials: the presence of fasciculations potentials is enough evidence of 
acute denervation in the similar way that one considers fibrillation potentials and positive 
sharp waves. (63) 
As the disease progresses and the anterior horn cells are lost, the more typical changes 
in motor unit potentials that are associated with ALS will be seen, including long duration, 
increased complexity, and reduced recruitment. Motor unit instability remains a 
prominent feature, and motor unit variability remains highly visible and audible 
throughout the course of ALS.  
Neuroimaging studies:  
UMN assessment has been made possible with advent of Functional imaging studies 
with blood oxygenation level–dependent (BOLD) functional MRI and 
magnetoencephalography which may reveal abnormal activity in motor and non-motor 
areas in ALS. Similarly, the role of transcranial magnetic stimulation (TMS), whether 
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used alone or in combination with diffusion tensor MRI (DTI), in the evaluation of the 
UMN system is undeniable.  
The LMN involvement is objectively assessed and very well documented by detailed 
NCV/EMG studies that are generally available at most centers. Decrease MUP firing rate 
may be the only evidence for UMN involvement in ALS that NCV/EMG can provide. But 
the challenge is to objectively demonstrate and quantify UMN involvement (64). Upper 
motor neuron (UMN) pathology often starts in the primary motor and premotor cortex, 
with secondary degeneration of motor fibers and gliosis along the corticospinal tract. It is 
often difficult to decide whether the UMN is involved. Both neurophysiological and 
neuroimaging techniques have been used to evaluate UMN pathology. 
The most important role for neuroimaging studies in ALS is to exclude structural, 
inflammatory, or infiltrative disorders that may mimic this disease, and therefore all 
patients should undergo appropriate imaging of brain and spinal cord to rule out any 
lesions in the brain parenchyma, lesions at the skull base, cervical myelopathy and 
thoracolumbar sacral radiculopathy.  
The diagnosis of ALS as seen previously needs both UMN and LMN signs. LMN signs 
can be diagnosed using electromyography there is no accepted marker for UMN signs. 
Clinical proof of UMN signs especially in early disease is difficult. (65) (66) (67)  
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Conventional MRI:  
Neuroimaging signs that may support the diagnosis of ALS but are not specific for ALS 
are hyperintensity extending along the corticospinal tracts, motor cortex showing 
hypointensity and cerebral atrophy. (65) (66) (67) 
Hyperintensity along the corticospinal tracts:  
In patients with ALS conventional MRI (using T2, PD and FLAIR sequences) 
hyperintensity is seen along the corticospinal tract. The corticospinal tract changes are 
usually best appreciated in the coronal views. They are seen as bilaterally increased 
signal which extend along the tract from the centrum semiovale to the brain stem. The 
frequency of this finding varies in different studies and ranges from 15 to 76 percent. 
Using a combination of T2, PD and FLAIR showed a sensitivity of 62 percent.  
 Fig 
2                                                           Fig 3 
T2 W axial: Hyperintensity extending along the corticospinal tract in the cerebral 
peduncles and along the corticospinal tract in the posterior limb of internal capsule. 
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As compared to the routine T2 sequences the proton density images has been reported 
to have a greater specificity. Cheung et al reported a specificity of 100% and a sensitivity 
of 41–60% using PD images which showed hyperintensity along the corticospinal tract 
(68).  
 
It has been reported that the hyperintensity along the corticospinal tracts can be seen in 
other diseases as well like Krabbe disease, adrenomyeloneuropathy and X-linked 
Charcot-Marie Tooth neuropathies. It has also been described in normal individuals as 
well (69).  
 
Hypointensity in the motor cortex:  
T2 weighted images have shown some hypointensity in the motor cortex in a few percent 
of cases. Hypointensity may be due to iron deposition which causes T2 shortening, 
gliosis or infiltration by macrophages. However these changes are neither specific nor 
sensitive for ALS pathology. It can be seen in healthy population as well as those with 
other degenerative diseases. Cortical low signal intensity is seen in the precentral gyrus 
on T2 or FLAIR called as the “motor dark line” or “hypointense rim”. These have been 
described as UMN involvement in advanced disease. (65, 66,  67, 69,  68) 
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Cervical cord:  
Anterolateral columns of the spinal cord also may shows hyperintensity on T1WI in 
patients with ALS. Anterolateral column hyperintensity has been noted in the intracranial 
portion also in patients who have predominantly UMN signs. (66)  
 
Diffusion tensor imaging: (DTI)  
Diffusion tensor imaging can be used to diagnose upper motor neuron involvement in 
patients with ALS. The changes within the tissue alter the DTI indices – FA and MD 
values. FA values will be decreased and MD will be increased with loss of normal 
neuronal structure and function. Damage and loss of motor neurons in the primary motor 
cortex along with axonal degeneration of the corticospinal tract, glial cell proliferation, 
expansion of the extracellular matrix contribute to the changes observed on DTI (70). 
Many studies have shown significant correlations between the DTI indices along the 
corticospinal tract in patients with ALS. (65, 22, 71, 72, 73, 74) 
 
The corticospinal tract is the most commonly studied region and a reduction in FA values 
within this have been reported in may studies. (74) The reduction in FA value as 
mentioned earlier is due to loss of normal neuronal integrity. Mean diffusivity values have 
shown to be increased in some studies (71, 72, 75) along the corticospinal tract ; 
however few studies have revealed no changes in the MD values (76).  
 
Sage et al. (75) showed that FA values were reduced at nearly all the levels within the 
corticospinal tract with was most significant at the level of the posterior limb of the 
internal capsule.  
 
30 
 
Few studies have demonstrated significant correlation with the severity and duration of 
the disease (71, 74, 76). However these findings are not consistently seen in all the 
studies. Toosy et al. (72) have shown no correlation between the markers of disability 
and diffusion tensor indices.  
DTI indices are routinely calculated from a voxel based analysis. Another recently 
developed technique known as the tract-based spatial statistics (TBSS) combines voxel 
based and tract based analysis is being recently used for the same. (65)  
 
There are many studies that also reveal that abnormalities of the DTI indices are not only 
seen in the corticospinal tract but in extramotor regions as well. These include the corpus 
callosum, white matter in the frontal and parietal regions, hippocampus and insula.(69, 
70, 75, 77, 78).  Agosta et al reported that the uncinate fasciculus has shown increased 
diffusivity values at the in patients who had ALS. This suggested that the behavioral 
abnormalities in ALS patients may be due to involvement of the uncinate fasciculus (23).  
Meta-analysis done by Li J et al comparing 145 healthy controls and 143 ALS patients 
showed that significant reductions of the FA values in the bilateral frontal white 
matter/cingulate gyrus and the posterior limb of bilateral internal capsule (79).  
 
When compared with healthy population there was a significantly lower value of FA in 
the cervical cord. This was also found to be correlated with the functional                  
rating scales (77). 
 
Corpus callosum has been shown to be involved in patients with ALS using DTI indices. 
The FA changes were most pronounced in the middle and posterior parts which connect 
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to the motor and premotor cortex. The involvement of the corpus callosum may be an 
earlier feature of the disease.  
 
These findings in the corpus callosum are not specific and may be seen in other 
conditions like hereditary spastic paraparesis. (70, 77) 
Patients with bulbar onset of ALS have shown more markedly reduced FA values. In 
patients with progressive muscular atrophy there were reduced FA values noted in the 
premotor cortex and corticospinal tracts. (70, 80) Thus this suggests that DTI may be 
good marker for clinically silent UMN involvement. In a study done by Ciccarelli et al 
shows those patients with primary lateral sclerosis had reduced FA values in the white 
matter adjacent the premotor cortex as compared with patients with ALS who had FA 
values reduced in the frontal region (81).  
 
Foerster et al. in 2012 compiled data and a meta-analysis was done on FA values in 
studies that compared healthy controls and ALS patients. They have reported that the 
use of DTI has only a modest role in making the diagnosis of ALS (82).  
 
There are few studies that have evaluated the role of DTI in the spinal cord in patients 
with ALS. In a study done by Valsasina P et al patients with ALS showed a lower FA 
values within the cord when compared with healthy controls; however there was no 
change in the MD values (83). They also found a significant correlation of the ALSFRS 
with FA values in the cord. Another study reported by Nair et al. also showed that the FA 
values were lower in the cord in patients with ALS and radial diffusivity was higher when 
compared with healthy controls. Radial diffusivity also correlated with the forced vital 
capacity and the functional rating scale in these patients (22). The degeneration in the 
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corticospinal fibers can lead to a modification of the degree of directionality, which can 
be detected by diffusion tensor MRI. Therefore, in degenerated white matter tracts of 
patients with ALS one would expect to find changes in the anisotropy of diffusion in 
comparison with healthy subjects. The fractional anisotropy correlates with UMN 
involvement in ALS patients. 
Studies have shown relation of DTI indices with cognitive involvement in ALS (84). The 
severity of apathy and behavioral changes in early ALS has been proven to correlate 
with atrophy in the prefrontal cortex, especially in the orbitofrontal and dorsolateral 
prefrontal cortices in Voxel Based Morphometry (VBM), and in the right frontal gyrus in 
DTI. The combined VBM and DTI techniques have revealed extra-corticospinal tract 
neuronal degeneration mainly in the frontotemporal lobe of ALS patients. In particular, 
follow-up examinations in these patients have showed that whole-brain DTI changes 
occurred predominantly in the regions of brain atrophy. These objective analyses were 
comparable with drop in clinical scores in frontal lobe tests when serially              
monitored (85, 86). 
Differential diagnosis includes disorders of motor neurons (eg, SMA), motor 
neuropathies – multifocal motor neuropathy with conduction block, CIDP, lead poisoning, 
Neuromuscular disorders, lesions in the central nervous system (Lyme’s disease, HTLV, 
Syringomyelia), myopathies (IBM) and various endocrine causes (10).  
The clinical findings pertaining to both upper motor neuron and lower motor neuron 
dysfunction which is not explained by any other disease process along with history 
suggestive of a neurodegenerative disorder, is suggestive of ALS.  
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The diagnosis of amyotrophic lateral sclerosis is mainly established through history and 
clinical examination alone. But since the diagnosis has a serious impact on the patient 
and family ancillary investigations are done to exclude other differential diagnosis. 
 
DIAGNOSIS* 
In May 1990, at El Escorial, Spain, the World Federation of Neurology established 
diagnostic criteria for ALS. These criteria include clinical, electrodiagnostic, and 
pathological components. The clinical criteria divide candidates into those with definite, 
probable, lab-supported probable, possible, and FALS based on a careful history and 
examination of four regions of the neuraxis: bulbar, cervical, thoracic, and          
lumbosacral (87). 
A patient is referred to as having “definite ALS” if there is clinical evidence of both UMN 
and LMN signs in three or more regions. “Probable ALS” is UMN and LMN signs in two 
regions. “Possible ALS” implies that a patient either has UMN and LMN signs in one 
region only or has UMN signs alone in two regions. In addition, “possible ALS” may be 
applied to those with LMN signs in two regions as long as these are detected rostrally to 
the UMN signs. “Probable ALS-laboratory supported” refers to those patients who have 
clinical evidence of possible ALS but also have EDX evidence of more widespread LMN 
involvement. Follow-up examinations may be helpful in assessing patients with ALS, as 
disease progression may move a patient up a category, clarifying the diagnosis. 
Signs of denervation in EMG, however, were regarded as equivalent to clinical signs of 
the lower motor neuron and it was suggested to delete the category “laboratory 
supported probable ALS” and to use only the category “probable ALS”. The essential 
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difference between the EEC and the Awaji Criteria is that the latter regard fasciculation 
potentials in muscles with chronic neurogenic EMG-changes in a clinical context fitting 
with ALS as sign of “active denervation” even in the absence of fibrillation potentials and 
positive waves. This improves the sensitivity of EMG studies considerably without 
increasing the rate of false positive diagnoses as has recently been demonstrated 
(88),(89), (90) 
Using both sets of criteria together, namely Revised El Escorial and Awaji Criteria; 
Carvalho and Swash demonstrated an increased sensitivity in the diagnosis of bulbar-
onset ALS from 38% with revised El Escorial alone to 87% when both sets of criteria 
were used. Another group achieved a specificity of over 95% when using both sets of 
criteria together (89, 91). 
Table-1.  EMG features of the revised El Escorial criteria 
Level of Certainty Regions Involved Level of Certainty Regions Involved 
Possible ALS 1 region 
Probable ALS 2 regions 
Probable ALS – Laboratory Supported 1 region clinically, 1 region 
electrodiagnostically 
Definite ALS 3 or 4 regions 
*Flowchart for diagnostic criteria and algorithm given in Appendix – 9 
The utility of DTI is that the anisotropy indices are rotationally invariant, that is, they are 
insensitive to the orientation of: the subject in the scanner, the diffusion gradients, and 
the laboratory coordinate system. As such, the quantitative anisotropy values obtained 
from different patients, at different times, and from different MRI systems should be 
directly comparable provided the same acquisition scheme is always used. Therefore, 
diffusion anisotropy measures are suited to monitoring the progression of UMN 
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involvement over time, which is helpful in evaluating the efficacy of novel pharmaceutical 
compounds (76). This implies that a single cross-sectional study may not be that 
informative as would a longitudinal study with serial follow up of patients. 
 
There is usually a delay in reaching the diagnosis due to insidious onset of the disease. 
Mean time of diagnosis from the onset is about a year. Diagnostic delay leads to delay in 
starting treatment and symptomatic therapy. The ascertainment of diagnosis of ALS and 
breaking the news to the patient and family members is very important and sensitive 
matter. Clinicians need to rule out conditions that may mimic ALS (92). 
 ALS – functional rating scale:  
Activities of daily living (ADL) can be assessed by using the clinical rating scales. Earlier 
Norris scale and the ALS severity scale were used. The two most commonly used ones 
are the Appel ALS rating and the ALS Functional Rating Scale (ALSFRS).  
 
The total Appel ALS score in a healthy individual is 30 and 164 in those patients who are 
maximally impaired. Survival of the patient can be predicted by the rate of change in the 
Appel ALS Rating Scale.(26, 93)  
 
ALS functional rating scale: The ALS Functional Rating Scale (ALSFRS) is a rating scale 
used to monitor disease progression and disability in patients with ALS. It is a relatively 
simple scale which can be done quickly. It assesses the patient’s capacities and varying 
levels of independence in the daily activities. It assesses bulbar and respiratory functions 
along with swallowing, speech, salivation, upper extremity functions (handwriting, cutting 
food and dressing), lower extremity functions (walking and climbing), and dressing 
36 
 
hygiene and ability to turn in bed. It can be administered by any health care worker. 
There are five choices in each choice has a score from 0 to 4. The total score can range 
from 40 (normal function) to 0 (unable to attempt the task). The ALS score correlated 
well with the quality of life and also predicted survival. Since there was disproportionate 
weighting to limb and bulbar functions, as compared to respiratory dysfunction in the 
original ALSFRS a new revised ALSFRS-R is used. ALSFRS-R has additional 
assessments of orthopnea, dyspnea and the need for ventilatory support. The revised 
ALSFRS- R has a minimum score of 0 and a maximum of 48. It correlates significantly 
with the quality of life (93). ALSFRS – R is enclosed in Appendix 3. 
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MATERIALS AND METHODS 
Study design:  
There are two parts in this study: 
1. Retrospective Cohort Analysis – Data of patient with the diagnosis of Sporadic 
Amyotrophic Lateral Sclerosis (ALS) during the last 10 years (2002-Oct 2012) was 
analyzed. The following were assessed: 
 Pattern of onset (upper limb onset, lower limb onset, bulbar onset),  
 Presenting features (weakness, wasting, fasciculations),  
 Progression & Outcomes (time to respiratory dysfunction, loss of ambulation, 
wheel chair bound) 
 Atypical features (sensory abnormality, Extra-motor abnormalities)  
 Investigations (electrophysiology and neuroimaging)  
Data source – OP / IP records, telephonic interview, Last medical report 
2.  Prospective Analysis – The upper motor neuron involvement was analyzed by:  
 Assessment of cognition (ACE-R, PGIMS, FAB, NIMHANS Battery) 
 Structural integrity of corticospinal tracts by Fractional Anisotropy (FA) by Diffusion 
Tensor Imaging (DTI). 
This was a cross sectional study with a prospective patient enrolment. There were two 
patient groups in this study namely, normative data group and ALS group.  
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Study period:  
The study period was from September 2012 to February 2013.  
 
Ethical clearance: Ethical clearance was obtained from the Institutional review board 
(ref no: IRB min number 8057).  
 
Study setting:  
The study patients were those who attended the Neurology outpatient clinic and patients 
who were admitted under the Department of Neurology at Christian Medical College & 
Hospital, Vellore  
 
Inclusion criteria:  
1. Normative data group: Patients aged 35-65 years who underwent MRI brain for any 
reason (E.g. head ache evaluation) and in whom the MRI showed no obvious 
abnormality (as reported by the radiologist) were recruited for generating normative data. 
In all these patients there was no history suggestive of motor system involvement or 
amyotrophic lateral sclerosis and no abnormal neurological findings clinically.  
3. Amyotrophic lateral sclerosis group: Patients of any age above 25 years who were 
diagnosed to have sporadic ALS using Revised El Escorial – Awaji Algorithm.  
 
Inclusion Criteria for Retrospective part of the study: 
Patients of Sporadic ALS evaluated (OP and IP) in CMC hospital in last 10 years 
(Diagnostic criteria – Revised El-Escorial criteria & Awaji-shima criteria) 
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Exclusion criteria for Retrospective Part of the study: 
Other Motor Neuron Diseases like   
Primary Lateral Sclerosis  
Flail arm and limb phenotype (Pure LMN variants)  
Motor neuropathy with conduction blocks  
Primary Muscular Atrophy 
Patients coming for an evaluation and undergoing investigations as part of standard 
of care (EMG/NCV, MRI Brain & cervical Spine and other relevant tests) were the 
potential subjects. After applying Revised El Escorial criteria, they were labeled as 
Sporadic ALS.  Functional scale (ALSFRS-R scale) was applied and correlated with 
above findings.  Each case was compared with age-matched and sex-matched 
healthy control. The control group was taken from general population as stated 
above. The scores of cognitive battery and FA were taken in cases as well as in 
controls and appropriate statistical tests were applied. The pattern of onset, spread 
and progression in prospective group was analyzed in detail. 
Outcomes – Mortality  
Exposures – Nil 
Confounders – Socioeconomic background, Education status, Family support, systemic 
co-morbidities 
Diagnostic Criteria – Appendix 9, Table 4 
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Informed consent: Informed consent was taken from all patients being enrolled in the study. 
The sample copy of consent form is given in Appendix 1, 2.  
MR data acquisition:  
Examinations were performed with 1.5-T MR imaging Philips (Achieva, Philips medical 
systems, Koninklijke Philips electronics, Netherlands) machine. None of the patients 
needed sedation or anesthesia for the MRI.  
DTI indices:  
The movement of water molecules is determined by the eigenvectors and eigenvalues (λ 
1, λ2, λ3). Eigenvalues represent the magnitude of water movement along the direction 
of the corresponding eigenvectors.  
 
Fractional anisotropy was calculated by the formula:  
√3/2 x √ (λ 1 – MD) 2 + (λ 2 – MD) 2 + (λ 3 – MD) 2  
---------------------------------------------------------------  
√ λ12 + λ22 + λ32  
 
The FA and the eigenvalues were provided by the soft ware available in the MRI 
console. 
 
  
Placement of ROI in normative data group:  
Levels at which the regions of interest (ROI) were placed include subcortical white matter 
just below the motor cortex (at the point at which the corticospinal tract is seen close to 
the gray matter), posterior limb of internal capsule (PLIC), anterior and posterior parts of 
the deep periventricular white matter, in the frontal lobe white matter bilaterally, cerebral 
peduncles in midbrain, and the pyramids in the medulla. The ROIs were also placed in 
the genu and splenium of the corpus callosum and in an area of normal white matter with 
in the right Centrum semiovale.  
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Fig 4 - ROI were placed at the following locations: Posterior limb of internal capsule [A]; 
cerebral peduncles [B]; Deep white matter at the periventricular region [C]; Pyramids [D] 
 
Placement of ROI in amyotrophic lateral sclerosis:  
Regions of interest were placed in the subcortical white matter just below the motor 
cortex (at the point at which the corticospinal tract is seen close to the gray matter), 
posterior limb of internal capsule, cerebral peduncles and pyramids bilaterally. 
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Sample size:  
The prevalence of Amyotrophic Lateral Sclerosis is around 3 -8 /100,000. Owing to the 
rarity of the disease the sample size was taken to be thirty five.  
 
In our tertiary care hospital approximately 30000 patients are being seen in the 
outpatient clinic in Neurology in one year. On an average there are around three to five 
patients per week with suspected amyotrophic lateral sclerosis and two to three 
confirmed cases of ALS per month documented in Neurology in-patient record & out-
patient clinic. 
 
 Statistical analysis:  
Statistical analysis was done with the SPSS soft ware (version 17, SPSS). Mean and 
standard deviation of the fractional anisotropy (FA) at different ROIs places were 
calculated for the patients in the two groups. The DTI indices in patients with 
Amyotrophic lateral sclerosis (ALS) were compared with the normative data. The 
Levine’s test for equality of variances was applied after which 2-tailed t-test was used for 
calculation of the p values to see if there were significant differences in the DTI indices 
within the patient group (ALS) when compared with the normal data. The correlation 
between the DTI indices and the disability scores in ALS patients was done using 
Pearson’s correlation and scatter plots. Nonparametric tests for independent variable - 
Kruskal-Wallis test and Mann-Whitney U tests were used in analyzing relation between 
ALSFRS-R scores and FA values against cognitive variables. 
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RESULTS 
RETROSPECTIVE GROUP: 
Baseline Characteristics: 
1. In the retrospective analysis, after search through our database of last 10 years, a 
total of 489 cases were registered (“motor neuron disease”, “pure motor 
syndrome”, “Amyotrophic lateral sclerosis”, “Motor Axonopathy”, “spastic 
quadriparesis with UMN and LMN"). Out of these, excluding the ALS mimics, pure 
LMN variants, Juvenile ALS, Familial ALS and accounting for the insufficient data 
- 286 Sporadic ALS cases were taken for analysis. (Fig. 5) 
FIG 5 
 
 
2. Approximately 75% of these were males and 25% were females. (Table-2) 
 
        Table -2. 
 Frequency Percent 
Males 215 75.2% 
Females   71 24.8% 
Total 286 100% 
                                                                          
 
3. These 286 cases range from 25yrs to 74yrs, mean of 48.7yrs. 
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4. The mean duration of illness at presentation was 16 months. (min: 1month, max: 
120months) 
5. The onset of illness was in Bulbar region in 25% (n =71), Upper limb in 39% (n = 
111), Lower limb in 34% and Mixed in 2% cases. (Fig. 6) 
Fig 6 
 
 
6. A significant proportion of patient with bulbar onset had rapid progression as 
compared to limb onset (p = .03). Mixed onset also had rapid progression. Lower 
limb onset had slower rate of progression. (Table-3) 
 
Table-3.  The Pattern of Onset & Pattern of Progression 
             Pattern of Progression Total 
Rapid - second 
region within 1 
month 
intermediate - second 
region b/w 3-6 months 
slow - second 
region after 6 
months 
Pattern of 
Onset 
Bulbar 13 37 21 71 
upper 
limb 10 81 20 111 
lower 
limb 6 57 34 97 
mixed 3 3 1 7 
Total 32 177 76 286 
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7. In most of the patient there was contiguous spread of regions for example Upper 
limb to lower limb and then to bulbar and finally respiration. Similarly, bulbar onset 
will progress to upper limb and then to lower limb. Few cases progressed by 
skipping a region also. (Table-5) 
 
Table-5.  The pattern of Progression 
UL   LL   Bulbar 111 (38.8%) 
LL  UL  Bulbar 92 (32.2%) 
Bulbar  UL  LL 67 (23.8%) 
LL  Bulbar  UL 06 (2.1%) 
UL  Bulbar  LL 06 (2.1%) 
Bulbar  LL  UL 03 (1%) 
 
8.  Approximately, 24% were hypertensive and 11% were known diabetic. 
9. Around 27% of patients were smoker and 12% used to consume alcohol. 
 
 
10. A few of them had exposure to miscellaneous toxins before diagnosis, esp. Heavy 
metals like lead, cadmium etc (5.2%) and few to chronic organophosphorus 
compounds (5.6%). Whereas, exposure to native medications (which have a base 
of heavy metals) after the diagnosis as an alternative therapy, was seen in 28% of 
cases. 
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11.  A history of weight loss was present in all patients except 2. Around 40% (n=113) 
had history of mild weight loss (<5kgs), 55% (n=158) had moderate weight loss 
(5-10kgs) and 5% (n=13) had severe weight loss (>10kg). 
 
12. Higher mental functions and cognitive analysis was limited to bedside tests 
namely – MMSE (Mini Mental Status Examination) and FAB (Frontal Assessment 
Battery). The mean MMSE score was 27.9. Around 7% showed abnormalities on 
FAB. 
 
13. Head drop was seen in 5% of patients. 7% had bladder problems in the form of 
urgency; hesitancy etc. 5% had extrapyramidal signs on examination.  
 
14. Myokymia was evident in 13%. There was significant correlation with exposure to 
toxins (native medications, Organophosphates, Miscellaneous toxin exposure) 
and presence of Myokymia on examination. The duration of exposure to native 
medication was around 2 – 5 months (mean 3 months). 
 
15. Sensory abnormality on examination was seen in less than 5% but abnormal 
SNAPs were evident in approx. 15% of cases. Out of these patients, 4 underwent 
Sural nerve biopsy which did not show any significant abnormality. 
 
 
16. Conduction block (at non-entrapment sites) was seen in 8.3% (n=22) across C8 
root. Only 2 of these had response to therapeutic trial with Immunomodulation. 
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17. Pulmonary Function Tests: 
Data was available for 100 patients. Among them 13% had normal results and 
47% had restrictive defect. About 39% were unable to perform because of severe 
bulbar weakness or bed-ridden state. (Fig. 7) 
 
Fig 7 
 
 
 
18. Barium Study was performed in 141 patients. Abnormal swallowing with laryngeal 
penetration was seen in 34 of them, out of which only 5 underwent PEG 
(Percutaneous Endoscopic Gastrostomy). (Fig. 8) 
 
Fig 8 
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19. Targeted investigations showed High CSF proteins in 20% of patients. The range 
of CSF protein was mild to moderate and none had more than 100mg%. 
 
20.  Less than 5% had autoimmune markers in their sera like ANA, ANCA, CRP, 
Complements (C3, C4). The commonest marker present was ANA. 
  
21. CPK was done in 109 patients (38%). There was mild to moderate elevation seen 
in 30% but none had significant elevation (>10 times the normal). 
 
22. MRI Cervical Spine was done in 259 patients. Only 4 cases (1.4%) had abnormal 
signals in the cord (Fig 9). MRI Brain was available for 231 patients. It was normal 
in 38% and showed abnormal signal along the corticospinal tracts (posterior limb 
of internal capsule, cerebral peduncles) in 12%.  
                          Fig 9. 
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23. Trial of therapy including pulse Cyclophosphamide was given in 52 patients, out of 
which 4 had response. 
 
24. PET CT data was available for only 14 patients. Out of these only 2 showed 
abnormal Brain metabolism – mainly frontal region hypometabolism. (Fig. 10) 
 
PET CT showing hypometabolism in bilateral frontal region  
 
Fig 10 
 
 
25. The outcome analysis showed that 4 patients had in-hospital mortality.  
26. Follow up data at 3 months was available for 59 patients (21%). Out of this, 10 
died, 40 worsened (ALSFRS-R) and 9 had no significant change in ALSFRS-R 
scores. 
27. Follow up data at 6 months or later was available for 48 cases (16.8%). Out of 
this, 10 died and 36 worsened.  
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28. There was no significant correlation between pattern of onset and mortality (follow 
up at 3 months, p = .418; follow up at 6 months, p = .225).  In other terms, 14% of 
bulbar onset cases either worsened or died at 3 months as compared to 18% of 
limb onset (UL + LL). This difference is due to difference in rate of progression. 
Most of the limb onset patients who worsened had involvement of bulbar region 
within a year of onset. Whereas the around 30% of bulbar onset had slow 
progression and remained confined to bulbar region even after 1 year of onset 
(second follow up). From this we also infer that not all bulbar onset cases 
progress rapidly to respiratory dysfunction, but a significant proportion of them 
actually remains confined to bulbar symptoms only.  
 
29.  The correlation between rate of progression and outcome was significant. 26% of 
rapid onset cases either worsened or died at 3 months as compared to only 16% 
of intermediate/slow onset ones. At subsequent follow up (6 months or later), this 
difference is even more.  
 
 
Thus, onset in a region does not necessarily imply worse prognosis but the rate of 
progression definitely affects outcome. In the table given below, despite onset in 
bulbar region, 4 patients did not worsen at 3 months but as the duration of the 
disease increases, the drop in ALS functional scores becomes conspicuous. At 
second follow up (at 6 months or later), most of the cases show worsening.  
(Table 6) 
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Table-6.Summary of ALSFRS-R scores at follow up visits 
 
ALSFRS-R  Same Worsened Deceased Total 
 B U L B U L B U L  
At Discharge        2 2 4 
F/U at 3m 4 2 2 7 17 15 3 3 3 56 
F/U at 6m 1 0 1 6 16 14 2 2 6 48 
Total  10 75 23  
B – Bulbar, U – Upper limb, L – Lower limb 
 
30. Diagnostic Categories: 182 patients were categorized as “Clinically definite ALS” 
according to Awaji criteria where as 87 of these were clinically definite according 
to El Escorial criteria. Thus supporting the notion that Awaji criterion increases the 
sensitivity of diagnosis. The sensitivity of Awaji Criteria was 68.2% and specificity 
was 86.9% where as sensitivity of El Escorial criteria was 41.6% and specificity 
89.6%. Around 30% cases jumped from one category to a higher category on 
application of Awaji criteria.(Table-7 & 8) 
 
Table-7. Comparison between the two Diagnostic Criteria 
 
Diagnostic Category Awaji Criteria Total 
Clinically 
Definite 
Clinically 
Probable 
Clinically 
Possible 
El Escorial 
Criteria 
Clinically Definite 88  0 88 
Clinically Probable 94 67 2 163 
Clinically Probable 
lab supported 1 16 9 26 
Clinically Possible 0 3 6 9 
Total 182 87 17 286 
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Table-8. Sensitivity & Specificity of the two Diagnostic Criteria 
Awaji & El Escorial Criteria Cross tabulation 
   El Escorial Criteria 
Total 
   Clinically 
definite/Clinically 
probable 
Clinically probable-lab 
supported/Clinically 
possible 
Awaji 
Criteria 
Clinically 
definite/Clinically 
probable 
Count 249 20 269 
    
% within elesco Sensitivity 68.2% 57.1% 94.1% 
Clinically possible Count 2 15 17 
    
% within elesco .8% Specificity 86.9% 5.9% 
Total Count 251 35 286 
 
PROSPECTIVE GROUP: 
 
1. A total of 34 patients fulfilled the inclusion criteria. They were recruited and 
compared with normative group. 
2. 56% (n=19) were male and 44% (n=15) were females. 
3. The mean age was 49.7yrs (min: 35, max: 67) 
4. The mean duration of the disease at presentation was 22 months. (min: 4m, max: 
84m). As the duration of the disease increases, there is worsening of ALSFRS-R 
scores. (Pearson correlation = -.373, p = 0.030) 
5. 20% were hypertensive and 6% were diabetic. The other baseline characteristics 
are given in the following Bar diagram (Appendix - 8) 
6. The region of onset was Upper limb in 15 (44%), Lower limb in 11 (32%) and bulbar 
in 8 (24%). This was similar to the distribution seen in retrospective group. 
7. There was mild to moderate CSF protein elevation in 6 out of 34 patients (17%)  
(Range 17 u/l to 84 u/l) and positive autoimmune markers (ANA, C3, C4) in 2.  
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8. Considering the pattern of onset and presentation in relation to history of high 
physical activity, we found that in all the 9 patients with history of high physical 
activity (occupation related or contact sports), the onset of the disease was in limbs 
(5 in upper limb and 4 in lower limb). 
9. Neuroimaging: MRI Brain and Spine were done in all 34 patients. None had any 
abnormality in cervical spinal cord other than age related spondylotic changes 
without evidence of significant root compression. 6 had abnormal MRI Brain in the 
form of non-significant scattered white matter changes or old lacunar infarcts. 8 had 
symmetrical hyperintensities in corticospinal tracts. 
10. The pattern of onset and progression is as shown in table given below. 44% (n=15) 
were upper limb onset, 32% (n=11) were lower limb onset and 24% (n=8) were 
bulbar onset.  
a. Rapid rate of progression was observed in 2 patients – both of which were 
lower limb onset.  
b. Slow progression was seen in 2 of the bulbar onset cases – both of these 
were females and the clinical findings remained localized to bulbar region 
even on follow-up. (Table-9) 
 
Table-9. Region of onset & Pattern of Progression Cross tabulation 
  
Pattern of 
progression 
Rapid - second 
region within 1 
month 
Intermediate - 
second region 
b/w 3-6 
months 
Slow - second 
region after 6 
months 
 
Region 
of onset 
Bulbar 0 6 2 8 
Upper limb 0 9 6 15 
lower limb 2 9 0 11 
Total 2 24 8 34 
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11. Root stimulation across C8 root was done in 24 of the patients, out of which 5 had 
evidence of conduction block ranging from 25% to 45%.  
 
12. The diagnostic criteria: Both Revised El Escorial and Awaji criteria were used.  
Awaji Criteria increased the yield of diagnosis. (91% were clinically definite ALS as 
compared to 82% with El Escorial criteria)  
13. Barium Study was done in 21 patients. 4 of these showed evidence of laryngeal 
penetration and 2 out of these underwent PEG implantation. 
14. PFT was done in 30 of 34 patients. 17 of these showed evidence of restrictive 
defect with low Forced Vital Capacities.(Fig 11) 
Fig 11 
 
 
15. Phrenic nerve conduction was done in 27 of 34 patients. The latency and amplitude 
of phrenic nerve conductions were tested against PFT by Kruskal-Wallis test 
(Nonparametric test for independent variables)  
 
It showed significant correlation between abnormal PFT and prolonged phrenic 
latencies (p = .041) as well as lower phrenic amplitudes (p = .044). 
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But when PFT was compared with bedside examination of palatal excursion and 
Gag reflex – there was no significant correlation between the two.  
 
16. Cognitive battery was attempted in all patients. The motor disability and spastic 
dysarthria was kept in mind while applying and interpreting the tests. Only the 
batteries which have established age and education based norms were used, 
namely PGI Memory scale, Addenbrooke’s Cognitive Examination- Revised (ACE-
R), Frontal Assessment Battery (FAB), and NIMHANS Battery.  
A significant number of patients (47%) showed abnormality in Auditory Verbal 
Learning Test (AVLT) and few showed evidence of Executive dysfunction (motor 
and language), and Planning and Judgment – on ACE-R (21%) and FAB (11%) 
(Fig.12) 
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Cognitive Assessment 
 
Fig12 
AVLT – Auditory Verbal Learning Test, FAB – Frontal Assessment Battery  
 
17.  Follow up data was available for 50% of cases. At first follow up (3 months), 5 out 
of 17 patients showed no or minimal change in their functional status (ALSFRS-R). 
At subsequent visits, all patients showed worsening except one. (Table-11) 
 
Table-11.Comparison of ALSFRS-R Scores at first & second follow up 
 
 
 
 
 
18. Therapeutic trial with Immunomodulation was given in 20 of the patients, out of 
which 1 showed response. 
19. DTI indices for normative group given in Appendix 10. 
 
 
 
 
 
 F/U at 3 months F/U at 6 months 
No follow up 17 21 
ALSFRS-R Same 5 01 
ALSFRS-R worsening 12 12 
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Table-12.  DTI indices in Amyotrophic lateral sclerosis: 
 
DTI indices in ALS patients and their correlation with normal data: 
 
        
ROI FA – 
Normative 
Group 
FA – ALS 
patients 
p value 
Right PLIC *  0.67 ± 0.05  0.64 ± 0.05  0.010  
Left PLIC *  0.69 ± 0.05  0.64 ± 0.03  0.000  
Right Cerebral peduncle  0.71 ± 0.07  0.66 ± 0.05  0.000  
Left Cerebral peduncle  0.74 ± 0.05  0.70 ± 0.05  0.010  
Right pyramid  0.58 ± 0.06  0.50 ± 0.05  0.000  
Left pyramid  0.58 ± 0.06  0.50 ± 0.05  0.000  
Right subcortex   0.58 ± 0.06  0.50 ± 0.05  0.000  
Left subcortex   0.58 ± 0.05  0.50 ± 0.07  0.000  
 
 
 
Table-13. Correlation of disease severity (ALSFRS-R) and DTI indices: 
Pearson correlation of the ALSFRS-R scores with FA: 
 
ROI Fractional Anisotropy 
 Pearson Correlation p value* 
Right PLIC -0.099 .577 
Left PLIC -0.011 .951 
Right Cerebral Peduncle -0.087 .625 
Left Cerebral Peduncle -0.171 .332 
Right Pyramid 0.071 .690 
Left Pyramid -0.121 .495 
Right Subcortex 
(at the region of the CST *)  
0.038 .830 
Left Subcortex 
(at the region of the CST *)  
-0.165 .230 
 
* p value: significance was calculated using the 2 –tailed t tests  
* CST- corticospinal tract, subcortical white matter just below the motor cortex 
A Pearson correlation was computed to assess the correlation between the DTI indices 
and  ALSFRS – R  which showed  that  there  was no statistically significant  correlation.  
(p value > 0.05). 
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20. The DTI indices were compared against the cognitive scores. Significant correlation 
between low FA values and abnormal cognitive scores were seen at two ROI – Left 
Cerebral Peduncle (p = .021) and at Right Pyramid (p = .006) (Table-14) 
      Table 14 Correlation between DTI Indices and Cognition 
DTI Indices (FA) Chi Square p value 
Right Subcortex 0.005 0.946 
Left Subcortex 2.016 0.156 
Right PLIC* 0.370 0.543 
Left PLIC* 1.553 0.213 
Right Cerebral 
Peduncle 
1.484 0.223 
Left Cerebral 
Peduncle 
5.039 0.021 
Right Pyramid 8.497 0.006 
Left Pyramid 0.658 0.417 
                                          PLIC – Posterior limb of internal Capsule 
 
20. ALSFRS-R scores were also compared with cognitive scores. There was no 
significant correlation between the two. (Table-15) 
Table 15   Correlation between ALSFRS-R scores and Cognitive Scores 
                  
 
 
 
 
 
 
Cognitive Battery Chi Square p value 
P.G.I. Memory Scale 10.333 0.666 
Frontal Assessment Battery (FAB) 18.167 0.151 
Addenbrooke’s Cognitive 
Examination - Revised (ACE-R) 
12.056 0.523 
NIMHANS Cognitive Battery 14.612 0.371 
Auditory Verbal Learning Test 
(AVLT) 
14.040 0.332 
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DISCUSSION 
Retrospective Group: 
The natural history of ALS has been studied in various parts of the world. In our study, 
the retrospective cohort comprised 489 consecutive patients with motor predominant 
neurological disorder. Out of these 286 cases of sporadic ALS from 2002 to 2012 were 
included in analysis. This was a very heterogeneous group.  
 
The gender distribution in this cohort was male predominant. Approximately 75% were 
male. This is similar to findings in other epidemiological studies (1). The mean age at 
presentation was 48 years which is almost a decade younger as compared to western 
data (10, 55).  
 
This fact can be attributed not only to genetic factors specific to our geography but also 
to environmental and host of other factors like exposure to toxins, heavy metals, native 
medication, fertilizers and insecticides. In this study about 5% patient had exposure to 
heavy metal toxins and 5% to chronic organophosphorus compounds. 28% of cases in 
retrospective study and 50% in prospective group were exposed to native medication as 
a means of alternative therapy for a minimum period of 3-6 months, at some point of time 
after diagnosis. Presence of myokymia on examination provokes us to elicit history of 
such exposures which serve as a “second hit” and may be causative in rapid rate of 
progression. There is no direct etiological correlation that has been proven but few 
studies from India describe similar exposure history in young patients with ALS (9), 91). 
The exposure to toxic substances and organophosphorus compounds is usually 
occupation related. The population affected by this is mostly rural, low education status 
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and very few use protective gear/clothing at their work places. Lack of personal 
awareness combined with lack of social and industrial initiative (for eg. Waste 
management) is a possible etiological factor and thus, a potential area which need 
urgent attention. 
This study found a trend towards younger age at onset and faster progression was seen 
among these cases that have been exposed to environmental toxins. There was a 
significant correlation (p<.05) between examination finding of Myokymia and history of 
exposure to these toxins. There is a significant correlation between exposure history, 
presence of myokymia and rapid rate of progression (p = .024). This fact has not been 
well documented previously in literature (21). 
 
Around 39% cases had onset in upper limb, 34% in lower limb and 25% in bulbar region 
and less than 2% had mixed onset disease. The less percentage of mixed onset cases 
may be attributed to the purely retrospective nature of the study. Otherwise, the 
distribution of patients is similar to findings in previous study (11)). In most of the patient 
there was contiguous spread of regions for example Upper limb to lower limb and then to 
bulbar and finally respiration. Similarly, bulbar onset progressed to upper limb and then 
to lower limb. This is similar to earlier documented pattern in literature (55). Few cases of 
spread by skipping of region were also seen, esp. lower limb to bulbar region. No major 
difference in rate of progression of disease was observed in this category. Fujimura et al 
(55) found 15% of cases of lower limb onset ALS spreading from lower limbs to bulbar 
skipping upper limbs. They also documented 37.5% of bulbar cases skipping to lower 
limbs. Similar to our study, they also didn’t find any significant difference in functional 
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scores or prognosis in these patients unless bulbar region is involved within 12 months 
of onset. 
 
It was possible to know the subsequent site of involvement with certainty in 73% of 
cases (n = 209). In approx. 72% cases, it was the contralateral limb that got involved 
next, whether the onset was in upper limb or in lower limb. That means spread was from 
one lower limb to next or from one upper limb to contralateral upper limb in 72% of 
cases. Turner M. R. et al found similar findings in their study on lower limb onset ALS 
where they documented initial progression either to the contralateral leg (76%) or 
ipsilateral arm (24%) (95). But this was not the case in study by Fujimura et al (55) in 
which they found 65% patients progressing from upper limb to lower limb or from lower 
limb to upper limb rather than contralaterally. 
 
In 15%, the ipsilateral arm or leg got involved depending on the region of onset – leg or 
arm, respectively. In rest of the 15%, the symptoms became more or less generalized 
after onset in a limb. This is different from what is documented in literature (95). 
Longitudinal studies of ALS have shown that the region of onset is the most severely 
affected, with spread towards the contiguous body regions, and that LMN and UMN loss 
occur independently of each other (96, 97). We, like others, observed in this study that 
sequential spread supports the concept of focal onset and radiating involvement of 
LMNs. 
 
The time taken from onset of first symptom to reach second symptom (O-SS) was 
variable (ranged from 1 month to 16 months). The median time was 6 months. The mean 
ALSFRS-R scores of cases with O-SS < 6 months was higher than in those with O-SS > 
6 months (38.34 & 31.57 respectively). Although p value was > 0.05, this showed a clear 
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trend that time taken to acquire second symptom / region is an indicator of poor 
prognosis. Similar conclusions were drawn by Turner et al and Fujimura et al              
also (55, 95). 
 
A statistically significant number of cases with bulbar onset had rapid progression as 
compared to limb onset (p < .05). This is in concordance to evidence in literature (55). 
Unfortunately, due to retrospective nature of the data, time to onset of respiratory 
dysfunction and cause of demise in most of the cases was not known. Also a higher 
number of females had bulbar onset as compared to males (31% & 22%, respectively). 
Studies also mention higher percentage of females as compared to males with bulbar 
onset ALS (10).  
 
The neurological examination at presentation was obviously a mixture of UMN and LMN 
findings. The pattern of weakness was distal to proximal in 94% of cases. Around 60% of 
patients at presentation had distal wasting in both upper and lower limbs. These were 
mainly of limb onset cases that were at least 4 months into the illness. As compared to 
these, the phenotype in bulbar variants was that of mild distal upper limb wasting with 
tongue atrophy and lower limb spasticity. No gender and age predominance was seen in 
this group although the progression was found to be slower. Reviewing literature, in the 
pure bulbar palsy phenotype typically affects women older than 65 years of age, the 
disease remains localized to oropharyngeal musculature and UMN features  
predominate (13). 
 
UMN predominant presentation i.e. “spastic quadriparesis” or “spastic syndrome” was 
seen in approximately 32% cases (n = 91). Their age distribution is as follows:- 
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Table 16 Comparison of early and late onset UMN Predominant ALS 
Age in 
years 
Total no. of 
cases 
Cases with 
predominant spasticity 
Mean ALSFRS-R 
scores 
25 – 40 77 19 (25%)-17 males, 2 females 38.564 
> 40  209 72 (35%)-48 males, 24 females 31.675 
  
Predominant spastic presentation was seen in all age groups. But gender distribution 
was suggestive of male predominance in age between 25 – 40 years. The mean 
ALSFRS-R scores were higher in younger age group. Studies have shown that young 
ALS presents with predominant UMN features and the rate of progression is slower in 
this group with higher mean ALSFRS scores, that is consistent with our findings         
also (98).  
 
Weight loss was observed in almost all cases. The correlation between severity of weight 
loss and rate of progression or the site of onset was not significant. Although, a very few 
of our patients were obese (3%), 8 out of 9 of them had slow progression. This finding is 
similar to earlier findings which lead to notion that over-weight and obesity can be 
protective of rapid progression of illness (92, 95). 
The various extra-motor features observed were bladder involvement in 7% and 
extrapyramidal signs in 5%. These were in concordance with known prevalence of non-
motor or extra-motor features in ALS (40, 100). 
 
Severe neck muscle weakness was present in around 17% of cases and 5% had 
historically and clinically “dropped-head-syndrome”. This percentage is higher as 
compared to earlier studies (101) that have reported a prevalence of 1.3%.  The age was 
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evenly distributed throughout the sample. This is also similar to the findings in literature 
(97). In most of these cases, there was of proximo-intermediate weakness and wasting 
of upper limbs. The tone was reduced in upper limbs but increased in lower limbs; a 
pattern that has been named as “Man in Barrel” appearance. Around 43% (n = 6) cases 
of these “dropped-head syndrome” had this phenotype.  
 
The revised El Escorial (World Federation of Neurology) criteria for the diagnosis of ALS 
do not allow abnormal sensory nerve conductions except in the presence of entrapment 
syndrome or coexisting peripheral nerve disease (87). Other studies have reported 
abnormal findings of the peripheral nervous system in ALS ranging between 13% and 
22% (102, 103, 104, 105). It has been well proven that ALS is not a pure motor 
syndrome but a heterogeneous multisystem disease with a significant sensory 
involvement. Thus we analyzed sensory system both clinically and electrophysiologically. 
Our study suggested that less than 5% patients report sensory complaints but abnormal 
SNAP (sensory nerve action potential) were seen in as many as 15%. In all the cases 
minimum four pair nerves were analyses (2 pair in upper limbs – median & ulnar; and 2 
pairs in lower limbs - superficial peroneal & sural). Sometimes radial nerve conduction in 
upper limbs was also done depending on the pattern of weakness and to differentiate 
from Brachial plexitis. Most of the patients with sensory complaints had normal sensory 
conductions whereas most of the patients with abnormal sensory conductions had no 
sensory complaints. 26% of them had diabetes and 26% consumed alcohol – both are 
potential confounding factors. But in none of the cases the pattern of involvement was in 
keeping with distal symmetric polyneuropathy (DSP) which is usually seen in Metabolic 
(like diabetes) or toxic neuropathy.  
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Four cases also underwent nerve biopsy – 3 out of which were reported normal (sural 
nerve). Vasculitic like changes on histopathology of nerve biopsy have been documented 
in ALS (20, 106) which  was not present in our case. 
 
The pathogenesis has been subjected to wide variety of speculations. Heads et al 
suggested that the primary pathology in the sensory peripheral nerve in ALS is dorsal 
root ganglion neuronopathy, resulting initially in progressive axonal atrophy followed by 
secondary demyelination and ultimately by axonal loss (107). 
 
Conduction block is an exception to the electrophysiological diagnosis of ALS. In our 
study, 8.3% cases had evidence of conduction block apart from entrapment sites. Mainly 
these were present on cervical root stimulation. Other co-morbidities like diabetes and 
paraproteinemia were absent. Serological evidence of Anti Ganglioside antibodies was 
absent (tested in 3% of cases). The clinical phenotype of these cases didn’t differ from 
classic ALS except for 2 patients who responded to trial of immunosuppressive therapy. 
This is in contrast to earlier defined phenotypes of these patients – of being more LMN 
predominant, slower progression and longer survival (61). Thus, many a times we find 
mixed cases in which inflammatory/autoimmune causes co-exist along with primary 
neurodegenerative pathology. These cases warrant immunotherapy and if given 
adequate trial, will respond to treatment.  
 
Autoimmune panel and markers of Vasculitis were available in 78% but positive only in 
2% (ANA, ANCA, Complements C3, and C4). Most of the studies of ALS provide some 
evidence of autoimmune mechanisms associated with the disease but it is not clear 
whether these alterations are pathogenic or a nonpathogenic epiphenomenon (108). 
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Most of the trials of immunosuppressive therapy in ALS have failed to show any 
significant response (109). Our study corroborates this fact further.  52 patients were 
given adequate trial with pulse Cyclophosphamide therapy but only 4 responded to it. 
The responses were more subjective than objective and can hardly be documented in 
terms of functional scale. No difference in survival outcomes were seen in those who 
responded to those who didn’t. 
It has been well established that cognitive dysfunction is a part of spectrum in ALS. But it 
is not that all patients will show cognitive abnormality. In most of them, even if we find 
any abnormality, it will be subtle. These evidences come after applying elaborate 
neuropsychiatric and cognitive scales. Approximately 30 - 50% of cases will have some 
cognitive dysfunction (50) even though they don’t fulfill the criteria for dementia. Up to 
15% of cases can be diagnosed as dementia (52, 110). The most common cognitive 
dysfunction is predominantly of dysexecutive in nature. The most common type of 
dementia known among ALS patients is behavior variant Frontal Temporal Dementia 
(bvFTD) (16). In the retrospective analysis, we found around 28% of cases showing 
abnormality on bed-side preliminary cognitive batteries like MMSE and frontal 
assessment battery (FAB). Out of these approximately 7% showed abnormal scores in 
most of the categories of the tests, and had unequivocal evidence of cognitive 
involvement. Most commonly, lexical fluency followed by conflicting instructions and go-
no-go task were affected. This shows that frontal executive, set-shifting and motor-
planning are affected and can be found even by means as simple as bed-side FAB, 
without need of elaborate scales, psychologists, psychiatrists etc. This has bearing not 
only on documentation and enrichment of epidemiological records but a direct effect on 
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management of an individual. Obviously, to label someone has having dementia, one 
needs fulfillment of complete criteria. These have been looked into in a small set of 
people (n = 34) in prospective analysis. There was no correlation between MMSE scores 
and abnormality on FAB and mean MMSE was 27. The group was heterogeneous in 
respect to the education status. Education is the most dominating confounding factor. 
58% of cases with poor education status (primary school and below), showed 
abnormality in FAB scores where as 84% of those who went to college or attained higher 
education scored normal on FAB. Although, statistically insignificant, there was a trend 
towards worse FAB scores as the duration of the disease increases. Despite insufficient 
data, one can derive a strong relation between abnormal frontal executive tests and 
advance ALS, keeping in mind one’s education status and duration of disease. The other 
potential confounding variables are spastic dysarthria in cases of abnormal lexical 
fluency.  
In this study, we had data on Barium study for 49% of cases (n = 141). Out of these, 
abnormal study was reported in a total of 53% and laryngeal penetration and high 
tendency to aspirate was seen in 24% of cases who underwent the study.  77% of bulbar 
onset cases of who underwent barium study showed abnormality as compared to 38% of 
limb onset cases. This was statistically significant (p = .05). There was a statistically 
significant correlation between worse ALSFRS-R scores and abnormal barium study (p = 
.007). This has been proven in earlier studies too (7, 57) that one of the main prognostic 
factors in any given setting is bulbar dysfunction. This also has direct bearing on quality 
of life, social health and depression (111). Pseudobulbar sign (exaggerated gag reflex) 
was seen in 45.5% of cases. 50% of these were emotionally labile.   
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Only 5 patients underwent Percutaneous Endoscopic Gastrostomy (PEG). Gastrostomy 
is one of the only management options that makes a significant difference in outcome 
and survival (46). It is safe and effective measure to prevent malnourishment, weight 
loss and aspiration. It can be done by interventional radiologists as well as by 
gastroenterologists (112). Management options in any bulbar ALS includes altering the 
texture of diet for bolus control purposes, compensatory swallowing strategies, changing 
eating habits (e.g., smaller portions, increased mastication time), and consideration for 
early PEG implantation (113). 
The data for pulmonary function test (PFT) was available for 100 patients (35%). Among 
them 86% had abnormal results (39 were not able to perform and 47 had restrictive 
pattern). Most of these were bulbar ALS cases (31%). The mean ALSFRS-R score in 
patients “unable to perform” PFT was 25, in patients with “restrictive defect” was 31 and 
in patient with “normal PFT” was 38. All the patients who died before discharge from the 
hospital had severe respiratory dysfunction (57, 114). Thus PFT is a cheap and good 
tool to prognosticate any patient with ALS. It can also be a effective monitoring tool as 
it’s a direct measure of one’s functional state, quality of life and thus, can significantly 
affect management options (115). But it is hard to interpret PFT in patients with severe 
bulbar weakness without limb involvement or in patients who are bed ridden without 
respiratory involvement. Most of these cases are not able to complete the test and PFT 
is not a good tool in these set of patients. Investigations and management have to be 
individualized. PFT can be correlated with phrenic nerve conduction parameters for early 
prediction of patient likely to end up in respiratory embarrassment (116). Unfortunately, 
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phrenic nerve conduction parameters were available only for 13 patients in retrospective 
group.  
 
CPK (Creatine phosphokinase) is raised in around 40% of cases of sporadic ALS (112). 
In our study, CPK values were known for 109 patients with a mean of 103 U/L. There 
was no significant correlation between CPK values and ALSFRS-R scores (p = .687). 
Earlier studies also have shown the similar results (117, 118). 
MRI of cervical spine and brain are done to rule out close mimics like cranio-vertebral 
junctional abnormalities, high cervical cord demyelination, parasagital lesions, 
adrenoleukodystrophy.  Except for 1.4% of cases, the rest showed normal cervical spine 
or insignificant cervical spondylotic/degenerative changes. In 12% of cases abnormal 
signals along corticospinal tracts (CST) was noted – posterior limb of internal capsule 
and cerebral penduncles. These abnormalities are observed frequently in normal 
patients and thus considered unreliable and inconsistent, and they do not correlate with 
clinical scores. T2-hyperintensity of the CST has low sensitivity (approximately ≤40%) 
and low specificity (approximately ≤70%) (20). FLAIR images increases the sensitivity on 
the cost of reduced specificity. Proton density images are not routinely used but said to 
have a better sensitivity as well as specificity in detecting abnormality in CST in ALS 
patients, esp. early into the disease. Newer techniques like Voxel based morphometry 
(VBM) and T1-weighted spin-echo magnetization transfer contrast (T1 SE MTC) have 
even higher sensitivity (80%) and specificity (100%) (119) 
The follow up data was available for 21% (n = 59) at 3 months and for 16.8% (n = 48) at 
6 months or later. ALSFRS-R scores showed worsening at 3 months and later. Those 
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with bulbar onset and advance age at onset had faster progression and lower ALSFRS-
R scores at follow up. The mean ALSFRS-R scores for patients above 60 years of age at 
first follow up was 27.93 and second follow up was 21.34. There was a significant 
difference in the ALSFRS-R scores at both the follow-ups between bulbar onset and limb 
(both upper and lower limb) onset cases (p = .032). Mortality ratio at second follow up 
was higher than first follow up but due to small number, it was not statistically significant. 
These findings are in concordance with other natural history studies (55, (120). Due to 
smaller number of cases above 60 years, the difference between ALSFRS-R scores at 
presentation between relatively young onset and late onset was not statistically 
significant. Although mortality was higher in group aged > 60 years, multiple systemic 
factors & co-morbidities were present that could confound this result. 
The two diagnostic algorithms were compared, namely Revised El Escorial criteria and 
Awaji-shima criteria. Both clinical and electrophysiological data were looked at. 
According to Awaji criteria, 64% patient fell into “clinically definite ALS” as compared to 
31% when El Escorial criteria were used. Thus sensitivity of the diagnostic algorithm was 
increased as was shown earlier (88), (89). The sensitivity of Awaji Criteria is 68.2% and 
specificity is 86.9% where as sensitivity of El Escorial criteria is 41.6% and specificity of 
89.6%. Applying the Mcnemar test (p = .001), about 30% of individuals shifted one 
category up the diagnosis ladder from El Escorial diagnostic categories. The measure of 
agreement kappa = .540. 
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PROPECTIVE STUDY 
In the prospective group, there were 34 patients. Their demography of the group and that 
of normative group was comparable without confounding or selection bias (Appendix-8). 
The distribution of males and females were almost equal (55% & 45%). The mean age 
was 49 years similar to retrospective group. 
 
The site of onset was upper limb in 43%, lower limb in 34%, and bulbar in 23%. This is 
similar to the pattern observed in retrospective group and other studies. The ALSFRS-R 
scores at presentation did not differ with region of onset. Contrary to what is known, at 
first follow-up, the scores were worse in upper limb onset cases as compared to bulbar 
onset ones. Studies done in west have shown worse scores with bulbar onset as 
compared to limb onset ALS (25), 42). Lower limb onset cases had higher ALSFRS-R 
scores and the progression was also slower (statistically significant difference between 
scores at 1st follow up).  
Table 17          ALS variants and comparison of serial functional scores 
Phenotype Number of 
patients 
n = 34 
ALSFRS-R at 
presentation 
(mean) 
First Follow 
up 
Second 
Follow up 
Classical ALS 17 34.65 29.23 19.34 
Pseudopolyneuritic 3 35.26 34.22 30.39 
Man-in-barrel 2 30.47 29.87 28.98 
Predominant UMN 6 36.58 33.27 30.76 
Predominant 
Bulbar 
4 38.69 37.19 33.78 
Hemiplegic Variant 2 29.87 26.65 23.71 
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The pattern of spread found in prospective group was different from observations in 
retrospective group. Excluding the 8 cases of bulbar onset and 3 cases in which data 
was insufficient – the rest of the 23 cases were analyzed. 15 cases had spread to 
ipsilateral side and 8 cases to contralateral side (accounting for both upper limb onset 
and lower limb onset cases). In retrospective group, the most common pattern of spread 
found was contralateral i.e., one upper limb to contralateral upper limb followed by lower 
limbs. But in prospective group, 45% cases first spread to ipsilateral limb (right upper 
limb to right lower limb) and only then went to contralateral side. Similar pattern has been 
documented by Fujimura et al where most of their cases spread from upper limb to lower 
limbs (55). 
Few cases with “skip-pattern” of progression were also present. It was interesting to 
observe that those who jumped from bulbar to lower limb had slower rate of progression 
(spread to subsequent site after 12 months) whereas those who jumped from lower limb 
to bulbar within 1 year had rapid rate of progression (spread to subsequent site within   
1-3 months or involvement of respiration). These few cases can give us insight into the 
pathogenesis of neuronal death – whether it occurs simultaneously in all regions or 
spreads contiguously from one region to other; whether the spread is centrifugal or goes 
outwards, like many earlier studies have postulated. This also shows that clinical 
presentation of an individual with ALS is not a direct representation of pathology at 
molecular level. Environmental and genetic factors also play a vital part in deciding the 
rate of progression, the spread and clinical phenotype. Obviously, when we see a patient 
in clinic, he is outcome of all the demographic, environmental and genetic factors. When 
we see a patient with ALS in later stages, the pathological state has already become 
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confluent. It is relatively easy to speculate retrospectively the nature of the disease but 
when a patient comes early into the illness, except for few known poor prognostic 
markers, it is very difficult to predict at what rate he will progress and what will be the 
next symptom. Only time can prove or contradict our predictions deriving a strong case 
for stringent and regular follow up. 
Amount of physical activity in premorbid life has been postulated to be a risk factor for 
developing ALS. The origin of this idea came from studying batting averages of Lou 
Gehrig just before he was diagnosed as ALS (121). 9 cases in this study had history of 
heavy physical activity (6 cases were occupation related and 3 had history of contact 
sports). The rate of progression or ALSFRS-R scores was did not correlate with history 
of heavy physical activity (p = .956). This is similar to findings in literature (121). Veldink 
et al (122) showed that amount of physical activity is not related to rate of progression 
and neither to functional scores.  
Turner et al (123) hypothesized that in most of the upper limb onset cases, the limb of 
onset was dominant one. But in lower limb onset cases, no such relation could be seen. 
Since routine physical demands on the upper limb are heavily influenced by limb 
dominance, whereas in the lower limbs the commonest function is standing or 
locomotion, which uses both legs equally. However, there may also be an inherent 
cortical vulnerability underlying upper limb-onset laterality, possibly influenced by 
changes in neuronal connectivity and cortical excitability in relation to handedness and 
reflected by the "split hand" phenomenon consistently observed in ALS.  
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The cognitive analysis comprised of 2 qualitative tests (FAB and ACE-R) and 2 
quantitative tests (PGIMS and NIMHANS Battery). The scores were compared with 
normative data (Appendix-7). The motor disability and spastic dysarthria was kept in 
mind while applying and interpreting the tests. Around 47% showed abnormality in at 
least one qualitative and one quantitative battery. But due to small sample size, the 
scores were heterogeneous and no one particular test came up as representation of 
cognitive abnormality in ALS. A rough generalization, though, could be made.  Most of 
the patients showed abnormality in three spheres – Language (lexical fluency) seen in 
35% of cases, execution, set shifting and planning (motor programming) in 25% of 
cases, and immediate recall & working memory in 40% of them. 
On the other hand, except for 3 patients none showed abnormality in visual memory & 
recall, visual recognition, long term percent retention (LTPR), construction ability, 
orientation, and visuo-spatial tests. Only one patient showed behavioral abnormalities 
and fulfilled Neary criteria for bvFTD (Behavior variant of Fronto-temporal dementia). 
This is similar to the findings suggested by Phukan et al (110) except that they found 
significant percent of cases having visuo-spatial abilities also. They studied a much 
larger group and their demography including age and duration of illness was very 
different from this group. Murphy et al divided ALS into ALS with cognitive deficits and 
ALS with behavioral deficits. They found different set of tests which were sensitive and 
specific for them. They also studied volumetric analysis of whole brain and found right 
hemisphere atrophy in most of these patients (124). 
 
The focus of most physicians and care-givers is on motor deficits and an emphasis is not 
made on the behavior and cognitive deficits. But studies have shown (52) that cognitive 
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profile of any ALS patient affects his management options, the compliance & response to 
treatment, and quality of life. Thus, demonstrating these extra-motor abnormalities is 
very essential. 
Pulmonary Function Test (PFT) was done in 30 patients. 17 of these showed evidence of 
restrictive defect with low Forced Vital Capacities. Phrenic nerve conduction was done in 
27 of 34 patients. The latency and amplitude of phrenic nerve conductions were tested 
against PFT by Kruskal- Wallis test individually. It showed significant correlation between 
abnormal PFT and prolonged phrenic latencies (p = .041) as well as lower phrenic 
amplitudes (p = .044). But when PFT was compared with bedside examination of palatal 
excursion and Gag reflex – there was no significant correlation between the two. 
When the DTI indices of patients with ALS were compared with the normative data there 
were lower FA values in all the regions of interest that were evaluated along the 
corticospinal tract. There was statistically significant correlation using t test in the 
subcortical white matter underlying the motor cortex in the region of the corticospinal 
tract (p value < 0.001), posterior limb of internal capsule (p value 0.009 and < 0.001), 
cerebral peduncle (p value <0.001 and 0.01) and the pyramids (p value < 0.001).           
A Pearson correlation was computed to assess the correlation between the DTI indices 
and ALSFRS – R which showed that there was no statistically significant correlation       
(p value > 0.05). The similar correlation was found in other studies too (72, (125). Thus, 
decreasing FA values along the corticospinal tracts is an objective estimation of UMN 
dysfunction in ALS. DTI plays a key role in evaluation of UMN involvement in ALS; it can 
be correlated with UMN scores (124) as well as with central motor conduction time. 
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The correlation between FA values and cognitive scores were tested with nonparametric 
test for independent variables (Kruskal-Wallis and Mann-Whitney U test). The result was 
statistically significant for FA value at right pyramid and left cerebral peduncle against 
categories of Cognitive scores (p = .006 & p = .021, respectively). The rest of the 
analysis didn’t draw statistically significant result. The reason for this may be several. 
Firstly, in our study DTI was done mainly to look for abnormalities in corticospinal tracts. 
The study was not designed to look for DTI indices and their correlation with cognition. 
For appropriate functional analysis of cognition and behavior, the ROI placement is quite 
different (extra-motor regions including association and limbic fiber tracts). Secondly, 
volumetric changes have been documented to have correlation between cognitive 
dysfunction and DTI changes rather than FA (126). 
The follow up data for prospective group was available for 50% of patients at 3 months 
and for 38% at 6 months. Except for 1 patient, all patients showed worsening on follow 
up (lower ALSFRS-R scores). The difference between scores at presentation as 
compared to scores at second follow up was statistically significant (p = .044). The 
difference between scores at first and second follow up were also significant (p = .001) 
but the scores at presentation and at first follow up were not significant (p = .29).  
ALS is a devastating disease with relentless progressive course and death in almost all 
cases within span of few months to few years. As we now know that it is a multisystem 
disease, optimum care for patients with ALS is provided with a multidisciplinary 
environment where physiotherapists, occupational therapists, speech therapists, 
respiratory physicians, gastroenterologists, and social workers collaborate to guide 
symptomatic management throughout the course of disease (127). 
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The standard of care in our hospital is not protocol based but targeted according to 
individualized need. It includes inputs from physiotherapists & occupational therapists for 
improving muscle strength (endurance enhancing and breathing exercises) and 
rehabilitating them for activities of daily living (ADL). Speech therapists and ENT 
consultants help in improving speech and swallowing techniques. Depending on the 
case, Gastroenterologists or interventional radiologists help for PEG placement for 
appropriate nutrition. In cases with significant respiratory involvement, Pulmonologist are 
called for planning of NIV or tracheostomy.  
 
Respiratory function and nutrition are crucial symptomatic concerns for patients with 
ALS, with respiratory failure being the main cause of death (128). Compared with 
patients managed in a general neurology clinic, patients managed in a specialized clinic 
had a better quality of life, possibly attributable to more effective use of resources, with 
benefits derived after a single visit (127).  
 
Thus, this study aims at forming a strong base for developing a protocol for care of ALS 
patients which is multidisciplinary including psychologist as well. This includes planning 
of management that is affordable and easily available throughout India. As patient pays 
from his pocket, a state based specialized ALS clinic may not be available in near future. 
In such a scenario, only after studying the natural history, symptomatology, cost of 
investigations and cost of treatment – we can make an attempt to form a local-need-
based cost-effective guidelines. 
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Table 18    Comparison between Retrospective and Prospective Data  
 
 Retrospective study 
(2002-2012) 
Prospective study (2013) 
Number of cases n = 286 n = 34 
Mean (age in years) 48 49 
Male: Female ratio 3 : 1 1.2 : 1 
Duration of disease (mean) 16 months 22 months 
Onset of disease Bulbar        – 25% 
Upper limb – 39% 
Lower limb – 34% 
Mixed         – 02% 
Bulbar        – 23% 
Upper limb – 43% 
Lower limb – 34% 
Rate of Progression Rapid            – 11% 
Intermediate – 62% 
Slow             – 26.5% 
Rapid           – 06% 
Intermediate – 64% 
Slow             – 30% 
Initial Spread Contralateral in 72% 
Ipsilateral in 15% 
Ipsilateral in 45% 
Contralateral in 23.5% 
Mean FS-SS duration 6 months 7 months 
Risk Factors 
Hypertension 
Diabetes 
Smoking 
Alcohol 
Heavy metal 
Organophosphorus 
Native medication 
Heavy Physical Activity 
 
24% 
11% 
27% 
12% 
5.2% 
5.6% 
28% 
No data 
 
20% 
06% 
17.6% 
11.8% 
8.8% 
11.8% 
52.9% 
26.4% 
Diagnostic Category 
El Escorial –  
Clinically definite 
Clinically Probable 
Clinically Probable Lab Sup 
Clinically Possible 
 
 
31% 
57% 
09% 
03% 
 
 
82% 
15% 
03% 
00 
Diagnostic Category 
Awaji Criteria 
Clinically Definite 
Clinically Probable 
Clinically Possible 
 
 
64% 
30% 
06% 
 
 
91% 
09% 
00 
Follow up at 3 months 
ALSFRS-R worse 
Died  
21% (n = 59) 
40 (68% of f/u pts) 
10 (17% of f/u pts) 
50% (n = 17) 
12 (71% of f/u pts) 
00 
Follow up at 6 m or later 
ALSFRS-R worse 
Died 
17% (n = 48) 
36 (75% of f/u pts) 
10 (21% of f/u pts) 
38% (n = 13) 
12 (93% of f/u pts) 
00 
Nonmotor manifestation   
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Head Drop 
Bladder 
Extrapyramidal 
Sensory symptoms 
Abnormal SNAPs 
Proximal Conduction block 
5% 
7% 
5% 
5% 
15% 
8.3% 
8% 
5% 
5% 
2.9% 
5.8% 
23% 
Barium Swallow 
Normal 
Laryngeal Penetration 
Abnormal Oral phase 
PEG Insertion 
n = 141 (49.3%) 
46.8% 
24% 
29% 
2% 
n = 21 (62%) 
65% 
12% 
23% 
6% 
Pulmonary Function Test 
Normal 
Restrictive 
Unable to do 
Phrenic Nerve Conduction 
Latency (mean) 
Amplitude (mean) 
n = 100 (35%) 
13% 
47% 
29% 
n = 13 (4.5%) 
6.43ms 
0.8mv 
n = 30 (88%) 
29% 
50% 
8% 
n = 12 (35%) 
7.43ms 
1.25mv 
MRI abnormal CST Signal 12% 23.5% 
PET Scan done 
Abnormal Brain metabolism 
05% 
                 40% (2 out of 5) 
14.7% 
6% 
Diffusion Tensor Imaging 
FA in ALS / Normative gr. 
FA along CST / ALSFRS-R 
FA along CST / Cognition 
Not part of the study n = 34 
Significant correlation 
No Significant correlation 
Significant correlation 
Cognitive Abnormalities 7% of cases. 
Dysexecutive and motor 
planning.   
47% of cases. Deficits in 
Language, Executive 
functions, Behavior. 
 
FS-SS        – Duration between First symptom – second symptom 
ALSFRS-R – ALS functional rating scale – revised 
CST           – Corticospinal tracts 
FA             – Fractional Anisotropy 
PGIMS      – PGI memory scale 
FAB           – Frontal Assessment Battery 
ACE-R       – Addenbrooke’s Cognitive Examination - revised 
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CONCLUSION 
1. The mean age of onset was 48 years which is almost a decade earlier than 
western data.  
 
2. ALS is a group of disorder with a wide spectrum of clinical features and significant 
heterogeneity in presentation. The onset of the disease was in upper limb in 39%, 
lower limb in 34%, and bulbar region in 25%. The spread from first site to next is 
usually contiguous (for instance, from upper limbs to lower limbs and from lower 
limbs to upper limbs) and rarely, skip pattern of spread is also seen.  
 
3. The rate of progression is best estimated by the duration between first symptom 
and second symptom. The rapidity of spread is most important prognostic factor. 
 
4. The rate of progression was found to be significantly rapid in bulbar onset ALS. 
But there were bulbar onset cases which remain confined to bulbar region. Thus, 
serial follow up is very important.  
 
5. ALS is now found to be a multisystem disease with involvement of bladder in 7%, 
extrapyramidal signs in 5%, sensory in 15% and cognition in at least 47% of 
cases. 
 
6. About 50% of cases in our study had cognitive dysfunction. The main spheres 
affected are Language, Execution, Planning and in few cases behavior. There is a 
statistically significant correlation between cognitive dysfunction and DTI indices. 
 
 
7. Several environmental and lifestyle factors were found that have not been studied 
well as yet, for example prior exposure to organophosphorus compounds and 
environmental toxins (seen in 5% of cases), as well as exposure to native 
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medications as an alternative therapy after the diagnosis. Around a third of our 
patients had history of exposure to native medications. There was a trend towards 
early onset, rapid progression and presence of myokymia on examination, in 
these cases.  
 
8. There was a significant correlation between abnormal PFT and low amplitudes of 
phrenic nerve conduction.   
 
9. Awaji-Shima Criteria, a modification of Revised El Escorial Criteria, increases 
yield of diagnosis (sensitivity increases), while preserving specificity. 
 
10. ALSFRS-R scores are a good measure of the severity and stage of ALS. It tells 
the rate of progression in an individual when the scores are serially followed. But it 
doesn’t include affective and cognitive dysfunction for which separate scales have 
to be used. It correlates with duration of disease, age of onset and rate of 
progression but not with DTI indices or cognitive scores. 
 
11. In patients with amyotrophic lateral sclerosis there are significantly lower FA 
values along the corticospinal tract when compared to normative data starting 
from the subcortical white matter. This proves and thus establishes the upper 
motor neuron involvement in these patients.  
 
12. There is no correlation between the DTI indices and the disease severity in 
amyotrophic lateral sclerosis in the present study. Diffusion tensor imaging is a 
useful modality in the objective estimation of UMN involvement and for serial 
monitoring of patients in ALS. 
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Appendix-1 
Christian Medical College, Vellore 
Department of Neurology 
 
 PATIENT INFORMATION SHEET 
 
A retrospective and prospective study of natural history, cognitive dysfunction and 
evaluation of upper motor neuron involvement in sporadic onset Amyotrophic Lateral 
Sclerosis (ALS) in patients treated at C.M.C. Hospital, Vellore. 
 
Introduction 
This study is being conducted by Department of Neurology, CMC Vellore. Amyotrophic 
Lateral Sclerosis is a common neurodegenerative illness. It causes weakness and 
wasting of various muscles of body over period of months to few years. It is 
heterogeneous condition and has many ways of presentation including different onset, 
different progression and involvement of different parts of body. The way it progresses 
also differs from person to person and depends on its onset. This disease usually 
involves motor weakness of various muscles of body but time and again, some non-
motor symptoms and signs have been described.  There is paucity of methodical 
research from India especially on the various non-motor manifestations of the disease 
like effect on one’s cognition and sensory system. With newer diagnostic modalities 
some aspect of the disease can now be evaluated and quantified in detail, esp. upper 
motor neuron component of its pathology. The better we know about its pathology and 
pattern of progression, we can prognosticate and plan management more accurately and 
in a more holistic as well as individualized manner.   
 
Methodology 
After detailed assessment by the Neurology Department, you will be asked to undergo 
few tests including – Clinical (neuropsychological assessment), Electrophysiological 
(Nerve conduction and Electromyography, and Imaging (MRI Brain including Diffusion 
Tensor Imaging) for further studies for understanding the plausible cause of your disease 
and to rule out other diseases that resembles ALS.  These tests may have to be 
repeated on your follow up visits. 
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Results 
 The result will be informed to the Neurologist who is primarily treating you.  The result 
will not change your management plans as these results cannot be used immediately on 
patients.   
 
Benefits  
This study could throw light into the mechanisms of disease manifestation, its 
progression, and other aspect of natural history of the disease, ultimately helping 
physicians to form a better management plan for the patients. 
 
Risks 
The above mentioned tests are standard non-invasive tests done in our Institution and 
therefore there are no risks for those involved in the study. 
 
Confidentiality 
All information regarding the individuals participating in this study will be treated as 
strictly confidential. No information regarding your result will be disclosed to any person 
not connected with either your care or this study. 
 
Volunteering for the study 
Participation in this study is entirely voluntary. Your participation or non-participation will 
not affect any further treatment provided to you in this hospital. 
 
Questions 
 If you have any doubts regarding the study you may clarify them now or contact 
either of the following: 
 
Dr Mathew Alexander Neurology Department        Phone: 0416-2282018 
 
Dr Varun Kataria Neurology Department                Phone: 0416-2282018 
 
Dr Sanjit Aaron,   Neurology                                   Phone: 0416- 2282018 
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Appendix-2 
CONSENT FORM 
 
  I, …………………………………… father / mother of 
………………………………. (Hospital number ………………) have been explained the 
details of the study as recorded in the Patient Information Form. I agree to participate in 
this study. All of my questions regarding the study have been answered satisfactorily. 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at any time without affecting my 
usual treatment or my legal rights  
I understand that my identity will not be revealed in any information released to third 
parties or published 
 
 
1. Signature / thumb impression of participant’s parent…………………………………         
 
Name: ………………………….    Date: …………………. 
 
2. Signature / thumb impression of witness……………………………………. 
 
Name: …………………………..    Date: ………………… 
 
3. Investigator’s signature …………………………        Date: ………………... 
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Appendix – 3 
 
THE ALS FUNCTIONAL RATING SCALE – REVISED: (ALSFRS – R)  
Measure Finding Points 
Speech Normal    
Detectable speech disturbance    
intelligible with repeating    
speech combined with non vocal communications    
loss of useful speech  
 
4 
3 
2 
1 
 
0 
Salivation Normal    
slight but definite excess of saliva in mouth;  
may have nighttime drooling  
  
Moderately excessive saliva: may have minimal 
drooling  
  
marked excess of saliva with some drooling    
marked drooling; requires constant tissue or 
handkerchief  
 
4 
3 
2 
1 
 
0 
Swallowing Normal    
early eating problems; occasional choking    
dietary consistency changes    
needs supplemental tube feedings    
nothing by mouth (NPO); exclusively parenteral or 
enteral feeding  
 
4 
3 
2 
1 
0 
Hand writing Normal    
slow or sloppy; all words are legible    
not all words are legible    
able to grasp pen but unable to write    
unable to grip pen  
 
4 
3 
2 
1 
0 
Cutting Food and 
handling utensils  
no gastrostomy/normal    
no gastrostomy: somewhat slow and clumsy but no 
help required  
  
no gastrostomy: can cut most foods although 
clumsy and slow; no help needed  
  
no gastrostomy: food must be cut by someone but 
can still feed slowly  
  
no gastrostomy: needs to be fed  
 
  
with gastrostomy: normal    
with gastrostomy: clumsy but able to perform all 
manipulations independently  
  
with gastrostomy: some help needed with closures 
and fasteners  
  
with gastrostomy: provides minimal assistance to 
caregiver  
  
4 
3 
 
2 
 
1 
 
0 
 
4 
3 
 
2 
 
1 
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with gastrostomy: unable to perform any aspect of 
task  
 
0 
Dressing and 
Hygiene  
Normal    
independent and complete self-care with effort or  
decreased efficiency  
  
intermittent assistance or substitute methods    
needs attendant for self-care    
total dependence  
 
4 
3 
 
2 
1 
0 
Turning in Bed and 
Adjusting bed 
Clothes  
Normal    
somewhat slow and clumsy but no help needed    
can turn alone or adjust sheets but with great 
difficulty  
  
can initiate but not turn or adjust sheets alone    
helpless  
 
4 
3 
2 
 
1 
0 
Walking    Normal 
early ambulation difficulties    
walks with assistance    
Non ambulatory functional movement only    
no purposeful leg movement  
 
4 
3 
2 
1 
0 
Climbing stairs Normal   
slow    
Mild unsteadiness or fatigue   
Needs assistance    
Cannot do  
 
4 
3 
2 
1 
0 
Breathing Normal    
Shortness of breath with minimal exertion (walking 
talking etc.)  
  
shortness of breath at rest    
intermittent (e.g. nocturnal) ventilatory assistance 
required  
 
ventilator dependent  
 
4 
3 
 
2 
1 
 
0 
Orthopnea No change    
Occasional shortness of breath, does not routinely  
use more than two pillows  
  
Require more than 2 pillows to sleep value    
Can only sleep sitting up    
Require the use of respiratory support (BiPAP®) to 
sleep  
 
4 
3 
 
2 
1 
0 
 
Respiratory 
Insufficiency 
No respiratory support value    
Intermittent use of BiPAP    
Continuous use of BiPAP at night    
Continuous use of BiPAP day and night    
Invasive mechanical ventilation  
 
4 
3 
2 
1 
0 
 
J.M. Cedarbaum et al. / Journal of the Neurological Sciences 169 (1999) 13 –21 
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Appendix-4 
Frontal Assessment Battery 
 
1. Similarities (conceptualization)  
“In what way are they alike?” 
 A banana and an orange 
 
(In the event of total failure: “they are not alike” or partial failure: “both have peel,” help 
the patient by saying: “both a banana and an orange are fruit”; but credit 0 for the item; 
do not help the patient for the two following items) 
 A table and a chair 
 A tulip, a rose and a daisy 
Score (only category responses [fruits, furniture, flowers] are considered correct) 
Three correct: 3  Two correct: 2  One correct: 1  None 
correct: 0 
 
2. Lexical fluency (mental flexibility) 
“Say as many words as you can beginning with the letter ‘S,’ any words except 
surnames or proper nouns.” 
If the patient gives no response during the first 5 seconds, say: “for instance, snake.” If 
the patient pauses 10 seconds, stimulate him by saying: “any word beginning with the 
letter ‘S.’ The time allowed is 60 seconds. 
Score (word repetitions or variations [shoe, shoemaker], surnames, or proper nouns are 
not counted as correct responses) 
> 9 words: 3  6 -9 words: 2  3 -5 words: 1  < 3 words: 0 
 
3. Motor series “Luria” test (programming) 
“Look carefully at what I’m doing.” 
The examiner, seated in front of the patient, performs alone three times with his left hand 
the series of “fist–edge–palm.” 
“Now, with your right hand do the same series, first with me, then alone.” 
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The examiner performs the series three times with the patient, and then says to him/her: 
“Now, do it on your own.” 
 
Score 
Patient performs six correct consecutive series alone: 3 
Patient performs at least three correct consecutive series alone: 2 
Patient fails alone, but performs three correct consecutive series with the 
examiner: 1 
Patient can’t perform three correct consecutive series even with the examiner: 0 
 
4. Conflicting instructions (sensitivity to interference) 
“Tap twice when I tap once.” 
To ensure that the patient has understood the instruction, a series of 3 trials is run: 1-1-1. 
“Tap once when I tap twice.”  
To ensure that patient has understood the instruction, a series of 3 trials is run: 2-2-2.  
The examiner then performs the following series: 1-1-2-1-2-2-2-1-1-2. 
Score   No errors: 3  1 -2 errors: 2  > 2 errors: 1 
Patient taps like the examiner at least four consecutive times: 0 
 
5. Go–No Go (inhibitory control) 
“Tap once when I tap once.” 
To ensure that patient has understood the instruction, a series of 3 trials is run: 1-1-1. 
“Do not tap when I tap twice.”  
To ensure that patient has understood the instruction, a series of 3 trials is run: 2-2-2. 
The examiner then performs the following series: 1-1-2-1-2-2-2-1-1-2. 
Score   No errors: 3  1 -2 errors: 2  > 2 errors: 1 
Patient taps like the examiner at least four consecutive times: 0 
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6. Prehension behavior (environmental autonomy) 
“Do not take my hands.” 
The examiner is seated in front of the patient. Place the patient’s hands palm up on his 
knees. Without saying anything or looking at the patient, the examiner brings his own 
hands close to the patient’s hands and touches the palms of both the patient’s hands, to 
see if he will spontaneously take them. If the patient takes the examiner’s hands, try 
again after asking the patient: “Now, do not take my hands.” 
 
Score 
Patient does not take the examiner’s hands: 3 
Patient hesitates and asks what he/she has to do: 2 
Patient takes the hands without hesitation: 1 
Patient takes the examiner’s hand even after he/she has been told not to do so: 0 
 
Interpreting results 
A cut off score of 12 on the FAB has a sensitivity of 77% and specificity of 87% in 
differentiating between frontal dysexecutive type dementias and DAT 
 
References 
Dubois, B.; Litvan, I.; The FAB: A frontal assessment battery at bedside. Neurology. 
55(11): 1621-1626, 2000.  
Slachevsky, A; Dubois, B. Frontal Assessment Battery and Differential Diagnosis of 
Frontotemporal Dementia and Alzheimer Disease. Archives of Neurology. 61(7): 1104-
1107, 2004. 
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Appendix- 5 
Pro forma for Postal Questionnaire   
 
Dear Mr.___________ (name of patient) 
Greetings from Department of Neurological Sciences: 
We are planning a study in Department of Neurological Science, CMC Vellore. The aim 
is to study various aspects of Motor Neuron Disease (also known as Amyotrophic Lateral 
Sclerosis). As you already are aware, this disease affects the motor nerves of the body 
causing weakness of various muscles of body. Unfortunately, there’s no cure for this 
debilitating disease. Thus, the better the understanding of the onset, progression, spread 
and outcome of this illness, the better will be management plan as well as more 
accurately one can predict and prognosticate its manifestations. For the same purpose, it 
would be highly beneficial if you can come for follow-up & assessment. I hope you will 
enthusiastically participate. 
In case you are not able to come to C.M.C. Hospital, Vellore, you can participate by 
filling the following questionnaire and sending it to “Department of Neurology, C.M.C. 
Hospital, Vellore, 632004.” The details and identity of each participant will be kept 
confidential. 
In case of unfortunate circumstances of demise of the patient, the immediate family 
members are requested to fill the details. This would not only help in better 
understanding of the disease, but also help us in proper individualized treatment & care 
of patients who are still suffering or will come to us for treatment.   
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PRO FORMA 
               DEMOGRAPHY: 
1. Name of Patient: 
2. Age: 
3. History of active participation in contact/field sports previously: 
4. Occupation: 
5. Family history:  
  Any family member suffering from similar illness? – if yes, please provide 
the detail 
  Any relative is suffering from other neurodegenerative illness? 
6. Last visit to C.M.C. Hospital, Vellore: 
7. Last visit to other physicians or neurologists (Please provide a scanned copy or 
photocopy of the prescription/clinical notes of your last medical minutes. 
 
CLINICALS: 
8. Handedness: 
9. Number of months / years into illness: 
10. At the onset of the disease, what was the chief problem -   
 Hand weakness 
 Leg weakness 
 Voice change 
 Difficulty in speaking and swallowing 
 
11. Medications: - Please state the number of months/years of each treatment taken 
and brief about their effect on your disease 
- Riluzole: 
- Steroids: 
- Immunomodulation/ Cyclophosphamide –  
- Any other –  
 
12. Outcome:  Current Activities of daily living – 
(1) Speech: Normal: 
Decreased clarity: 
Severe problem: 
No useful speech: 
 
(2) Salivation: Normal 
Increased: 
Marked drooling:  
(3) Swallowing: No problem: 
Mild difficulty/occasional choking: 
Effortful and change in consistency 
(4) Handwriting: Normal: 
Slow and sloppy: 
Able to grasp pen but not able to 
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of food: 
Tube feeding: 
 
write: 
Unable to grasp pen: 
(5) Cutting food and handling utensils - 
normal: 
Slow and clumsy: 
Food to be cut by somebody else 
but can feed himself: 
Has to be fed by someone: 
(6) Dressing and hygiene – Normal: 
Independent but requires more 
effort: 
Requires occasional assistance: 
Dependent on others: 
(7) Turning in bed and adjusting bed 
clothes - Normal: 
Slow and clumsy: 
Requires help; 
Dependent on others: 
(8) Walking – Normal: 
Mild difficulty: 
Requires assistance: 
Nonambulant: 
(9) Climbing stairs – Unaided: 
Slow and mild difficulty: 
Needs assistance: 
Cannot walk on stairs: 
(10) Breathing – Normal: 
Shortness of breath on exertion: 
Shortness of breath on lying down 
(requiring more than one pillow): 
Requires ventilator assistance 
(CPAP/BiPAP): 
 
  
 
 
Contact Details: 
Dr. Varun Kataria 
Department of Neurological Sciences 
C.M.C. Hospital, Vellore 
Tamil Nadu, 632004 
Phone: 04162282018 
           : 09488343346 
Email: varunkataria@rediffmail.com 
          : neurology@cmcvellore.ac.in 
 
 
102 
 
Appendix- 6 
PROFORMA 
               DEMOGRAPHY: 
13. Name: 
14. Age: 
15. Address: 
16. Occupation:  
17. Life style:   
                  Sports and Manual Activity: 
                  Alcohol Consumption: 
                  Smoking / Tobacco: 
18. Diet: 
19. Educational background: 
20. Family history: 
 
 
CLINICALS: 
 
21. Age at onset: 
22. Number of months / years into illness: 
23. Course – Upper limb onset – distal/proximal                    
- Lower limb onset – distal/proximal 
- Bulbar onset – voice/swallowing/breathing 
24. Motor system examination – MRC grading of muscle power**, Deep tendon 
reflexes, clonus. 
25. Sensory examination: 
26. Fasciculations: 
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27. Clinical spectrum:  
Cognition – MMSE, Frontal lobe battery*, Neary Criteria** 
Extrapyramidal features: 
 Cranial nerves: 
Tone & spasticity: Generalized / lower limbs only  
Pattern of muscle wasting – distal/proximal  
Sensory system – clinical, ENMG (SNAPs) 
Autonomic system – bedside tests, SSR 
 
28. ENMG: -  
29. MRI C-spine, Brain: 
30. PET Scan: 
31. DTI Scan and indices: 
 
EL ESCORIAL CRITERIA: 
AWAJI CRITERIA: 
 
32. Medications: -  
- Riluzole 
- Steroids 
- Immunomodulation 
 
33. Outcome: ADLs / dependence / current occupation (ALSFRS-R)* 
------------------------------------------------------------------------------------------------------------ 
* Given in Appendix3, 4 
** Given Below 
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                      MRC Motor Power Grading 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neck  
Flexion 
Extension     
  
Trunk   
Shoulder 
Abduction 
Adduction 
Flexion 
Extension 
  
Arm 
Flexion 
Extension 
  
Wrist 
Flexion 
Extension 
  
Hand Grip   
Small muscles of hand 
Median 
Ulnar 
  
Hip 
Flexion 
Extension 
Abduction 
Adduction 
  
Knee 
Flexion 
Extension 
  
Foot 
Dorsiflexion 
Plantarflexion 
Inversion 
Eversion 
  
EHL / EDB   
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Consensus criteria for FTD 
I. Core diagnostic 
features 
A. Insidious onset and gradual 
progression 
B. Early decline in social interpersonal 
conduct 
C. Early impairment in regulation of 
personal conduct 
D. Early emotional blunting 
E. Early loss of insight 
II. Supportive 
diagnostic features 
 
A. Behavioral disorder 
1. Decline in personal hygiene and 
grooming 
2. Mental rigidity and inflexibility 
3. Distractibility and impersistence 
4. Hyperorality and dietary changes 
5. Perseverative and stereotyped 
behavior 
6. Utilization behavior 
B. Speech and language 
1. Altered speech output 
a. Aspontaneity and economy of 
speech 
b. Pressure of speech 
2. Stereotypy of speech 
3. Echolalia 
4. Perseveration 
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5. Mutism 
C. Physical signs 
1. Primitive reflexes 
2. Incontinence 
3. Akinesia, rigidity, and tremor 
4. Low and labile blood pressure 
D. Investigations 
1. Neuropsychology: impairment on frontal lobe tests without severe 
amnesia, aphasia, or perceptuospatial disorder 
2. Electroencephalography: normal on conventional EEG despite 
clinically evident dementia 
3. Brain imaging (structural and/or functional): predominant frontal and/or 
anterior temporal abnormality 
 
- Consensus criteria for FTD (based on Neary, 1998) 
 
 
 
 
 
 
 
 
 
 
 
107 
 
Appendix - 7 
COGNITIVE SCORES: 
 
SCALE NORMATIVE  ALS GROUP 
P.G.I.M.S. (PGI Memory Scale) 
Remote Memory 
Recent Memory 
Mental Balance 
Attention & Concentration 
Verbal retention for similar pairs 
Verbal retention for dissimilar pairs 
Visual retention 
Visual recognition 
 
5.75 ± 0.52  
4.9 ± 0.31 
7.83 ± 1.66 
 
9.77 ± 1.74 
 
4.53 ± 0.73 
 
12.33 ± 2.44 
 
10.33 ± 2.50 
 
8.87 ± 1.25 
 
 
Frontal Assessment Battery (FAB) 
Conceptualization 
Mental Flexibility 
Motor Programming 
Sensitivity to interference 
Inhibitory Control 
Environmental Autonomy 
 
3 
3 
3 
3 
3 
3 
 
NIMHANS Battery for Adults (2004) 
Focused Attention (Color Trails Test) 
Verbal Learning & Memory (AVLT) – Recall & 
 
> 15th percentile 
> 15th percentile 
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Recognition trials 
Immediate Recall 
Delayed Recall 
Long Term Percent Retention (LTPR)  
Visual Learning & Memory – Complex Figure test 
Copy 
Immediate recall 
Delayed recall 
 
> 15th percentile 
> 15th percentile 
> 15th percentile 
> 15th percentile 
> 15th percentile 
> 15th percentile 
> 15th percentile 
Addenbrooke’s Cognitive Examination – 
Revised (ACE-R) 
Attention and orientation 
Memory 
Fluency 
Language 
Visuo-spatial 
 
 
 
Normal 
Normal 
Normal 
Normal 
Normal 
 
TOTAL   
 
 
 
 
 
 
109 
 
Appendix - 8 
Demography- Normative and Disease group 
 Normative Group ALS Group 
Number 25 34 
Age 45 ± 12 years 49 ± 15 years 
Sex 60% male, 40% female 55% male, 45% female 
Education 
School 
College 
Post graduate 
 
10 
7 
8 
 
8 
12 
14 
Risk Factors 
Diabetes 
Hypertension 
Smoking 
Alcohol 
 
4 
10 
4 
3 
 
2 
7 
6 
4 
Neurological Problem Headache, vertigo, 
Nonspecific complaints 
 
Neurological Examination 
including cognition 
Normal  
MRI 18 – normal  
07 – nonspecific white 
matter changes 
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Appendix – 9 
The diagnosis of Amyotrophic Lateral Sclerosis (ALS) requires 
A. The presence of:  
(A: 1) evidence of lower motor neuron (LMN) degeneration by clinical       
electrophysiological or neuropathologic examination,  
(A: 2) evidence of upper motor neuron (UMN) degeneration by clinical examination, and  
(A: 3) progressive spread of symptoms or signs within a region or to other regions, as         
determined by history or examination, together with 
B. The absence of:  
(B: 1) electrophysiological and pathological evidence of other disease processes that 
might explain the signs of LMN and/or UMN degeneration, and  
(B: 2) neuroimaging evidence of other disease processes that might explain the 
observed clinical and electrophysiological signs. 
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An evaluation of neurophysiological criteria used in the diagnosis of Motor Neuron Disease 
Douglass CP, Kandler RH, Shaw PJ and McDermott CJ 
Journal of Neurology, Neurosurgery & Psychiatry 81, 6 (2010) 646 
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Table 4 
Summary of the Revised El Escorial Criteria and Awaji Criteria for ALS  
 
Diagnosis: Differences between Awaji-Shima Consensus Recommendations 
and the Revised El Escorial Criteria (Airlie-House 1998)  
The diagnosis of ALS requires:  
Principles of the Revised El Escorial 
Criteria            
Principles of the Awaji Shima Consensus                                                 
Recommendations 
   Evidence of LMN loss (Reduced 
interferential pattern on full contraction 
and increased firing rate) 
   Evidence of LMN loss (Reduced 
interferential pattern on full contraction 
and increased firing rate) 
Evidence of re-innervation (motor units of 
large amplitude and longer duration) 
Evidence of re-innervation (motor units of 
large amplitude and longer duration) 
Fibrillations and sharp waves Fibrillations and sharp waves or 
fasciculation potentials 
No. of muscles affected by Region:  
Cervical and Lumbosacral region: minimum of 2 muscle innervated by different roots 
and nerves  
Bulbar and Thoracic region: a minimum of 1 muscle 
 Diagnostic Classification:  
Clinically definite ALS is defined by clinical or electrophysiological evidence by the 
presence of LMN as well as UMN signs in the bulbar region and at least 2 spinal 
regions or the presence of LMN and UMN signs in 3 spinal regions. 
 
  
 
Clinically probable ALS is defined on clinical or electrophysiological evidence by LMN 
and UMN signs in at least 2 regions with some UMN signs necessarily rostral to 
(above) the LMN signs. The revised El Escorial Criteria have an additional category 
“Probable ALS–Laboratory Supported,” which is defined when clinical signs of 
UMN and LMN dysfunction are found in only 1 region but electrophysiological signs of 
LMN loss are observed in >2 regions. 
Clinically possible ALS is defined when clinical or electrophysiological signs of UMN 
and LMN dysfunction are found in only 1 region or UMN signs are found alone in >2 
regions or LMN signs are found rostral to UMN signs. 
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Appendix 10 
DTI indices: 
Normative group: 
 
ROI  FA (Mean ± SD)   
  
MD (Mean ± SD)  (10 – 3 
mm2/sec)   
Genu   0.81 ± 0.05   0.97 ± 0.07   
Splenium   0.82 ± 0.04   0.93 ± 0.08   
Right centrum semiovale (normal appearing 
white matter) *   0.47 ± 0.04   0.92 ± 0.08   
Left PLIC **   0.69 ± 0.05   0.88 ± 0.07   
Right anterior periventricular white matter   0.49 ± 0.05   0.93 ± 0.08   
Left anterior periventricular white matter   0.5 ± 0.05   0.88 ± 0.08   
Right posterior periventricular white matter   0.55 ± 0.06   0.95 ±0.07   
Left posterior periventricular white matter   0.55 ± 0.05   0.94 ± 0.07   
Right Cerebral peduncle   0.71 ± 0.07   0.92 ± 0.07   
Left Cerebral peduncle   0.74 ± 0.05   0.94 ± 0.09   
Right pyramid   0.58 ± 0.06   0.88 ± 0.09   
Left pyramid   0.58 ± 0.06   0.88 ± 0.10   
Right subcortex   
(at the region of the CST ***)   
0.58 ± 0.06   0.91 ± 0.10   
Left subcortex   
(at the region of the CST ***)   
0.58 ± 0.05   0.89 ± 0.09   
Right frontal lobe   0.49 ± 0.07   0.95 ± 0.08   
Left frontal lobe   0.49 ± 0.08   0.90 ± 0.07   
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Appendix – 11 
 
Key for the Master Chart 
Retrospective Group, n = 286 
Prospective Group, n = 34 
1. Sex - 0 = male 
         1 = female 
2. Onset – 0 = Bulbar 
               1 = Upper limb 
               2 = Lower limb 
               3 = Mixed 
3. Progression1 – 0 = UL-LL-Bulb 
                            1 = LL-UL-Bulb 
                            2 = Bulb-UL-LL 
                            3 = LL-Bulb-UL 
                            4 = Bulb-LL-UL 
                            5 = UL-Bulb-LL 
4. Progression2 – 0 = Nonprogressive 
                            1 = Rapid 
                            2 = Intermediate 
                            3 = Slow 
5. Education – 0 = illiterate 
                  1 = Primary School 
                  2 = Secondary School 
                  3 = College 
                  4 = Graduate 
 
  
6. Hypertension  0 = Absent; 1 = Present  
7. Diabetes         0 = Absent; 1 = Present 
8. Smoking         0 = Absent; 1 = Present 
9. Alcohol           0 = Absent; 1 = Present 
10. IHD                 0 = Absent; 1 = Present 
11. Native Medication 0 = Absent; 1 = 
Present 
12. Organophosphorus 0 = Absent; 1 = 
Present 
13. Toxins           0 = Absent; 1 = Present 
14. Obesity         0 = Absent; 1 = Present 
15. Sports           0 = Absent; 1 = Present 
16. CVS examination 
0 = Normal; 1 = Abnormal 
17. Respiratory system  
0 = Normal; 1 = Abnormal 
18. Abdomen 0 = Normal; 1 = Abnormal 
19. Weight Loss – 0 = <5kg 
                          1 = 5-10kgs 
                          2 = >10kgs 
20. Neck Height Ratio – 0 = normal; 1 = 
low 
21. Eye movement – 0 = normal; 1 = 
Abnormal 
22. Facial Nerve -   0 = normal; 1 = 
Abnormal 
23. Head drop -       0 = Absent; 1 = 
Present 
24. FAB Frontal assessment battery –  
0 = Not done 
 1 = Normal 
2 = Abnormal Similarities 
3 = Abnormal Lexical Fluency 
25. Trigeminal Nerve 
0 = Normal 
1 = Motor Weakness, esp. jaw 
2 = Abnormal facial sensation 
3 = Brisk jaw jerk 
 
     26.  Palatal Examination 
0 = normal 
1 = gag sluggish 
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4 = Abnormal Luria’s test 
5 = Abnormal Go-no-go 
6 = Abnormal Conflicting 
instruct 
7 = Environmental Autonomy 
8 = 2 or > 2 categories 
abnormal 
2 = gag exaggerated  
      27.  Wasting –  
0 = in distal upper limbs only                                
1 = in prox and distal ULs                                
2 = in lower limbs  
3 = UL and LLs 
4 = No wasting 
5 = over UL and tongue  
      28. Spasticity 
                        0 = Normal 
1 = spasticity in LLs 
 2 = in ULs and LLs 
3 = Hypotonia 
       29.  Pattern of weakness 
0 = distal to proximal 
1 = proximal to distal 
2 = simultaneously 
26. Deep tendon Reflex 
0 = normal 
 1 = brisk 
2 = sluggish   
27. Plantar reflex, right and left 
0 = flexor 
1 = extensor 
28. Sensory system  
0 = normal 
1 = abnormal 
29. Cerebellar signs 
0 = absent 
1 = present 
30.  Romberg’s sign 
0 = absent 
1 = present 
31. Gait 
0 = normal 
1 = assisted 
2 = spastic 
3 = non ambulant 
32. FascicsH – History of fasciculation 
0 = Absent 
1 = present 
33. FascicsE – Fasciculations on 
Examination 
0 = Absent 
 1 = Present 
34. SNAP – Sensory nerve action potential 
0 = normal 
1 = abnormal  
35. Biopsy of nerve/ muscle 
0 = not done 
1 = normal 
2 = Vasculitis like 
3 = nonspecific inflammation  
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36. ActDener – Active denervation 
according to El Escorial criteria 
0 = absent / insufficient data 
1 = 1 region only 
2 = 2 regions 
3 = 3 or >3 regions 
37. ChrDener – Chronic denervation 
0 = absent / insufficient data 
1 = 1 region only 
2 = 2 regions 
3 = 3 or >3 regions 
38. Elesco – Diagnostic Category 
according to El Escorial criteria 
0 = Clinically Definite 
1 = Clinically Probable 
2 = Clinically Probable Lab supported 
3 = Clinically Possible 
39. ActDener1 – Active denervation 
according to Awaji Criteria 
0 = absent / insufficient data 
1 = 1 region only 
2 = 2 regions 
3 = 3 or >3 regions 
40. Awaji Criteria Diagnostic category 
0 = Clinically Definite 
1 = Clinically Probable 
2 = Clinically Possible 
41. ChrDener1 – Chronic denervation 
0 = absent / insufficient data 
1 = 1 region only 
2 = 2 regions 
3 = 3 or >3 regions 
42. Proxconduc – Root stimulation / 
proximal conductions 
0 = done 
1 = not done 
43. Condbloc – Conduction block 
0 = absent 
1 = Present at entrapment sites 
2 = present apart from entrapment 
sites 
3 = present on root stimulation  
44. Spirometry 
0 = Normal 
1 = Restrictive 
2 = Obstructive 
3 = Not able to perform 
4 = not done 
45. Barium – Barium swallow 
0 = not done 
1 = normal 
2 = Aspiration/Laryngeal penetration 
3 = Abnormal oral phase only 
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46. Immune – Autoimmune markers 
0 = not available 
1 = negative 
2 = positive 
47. Toxscrn – Toxin screening in 
blood/urine 
0 = not available 
1 = negative 
2 = positive 
48. PEG – Percutaneous Endoscopic 
Gastrostomy 
0 = Not Required 
1 = Required but not done 
2 = Done 
3 = Not done – reason unknown 
49. MRI1 – MRI cervical spine 
0 = Not available 
1 = Normal (including cervical disc 
changes but no significant root or cord 
compression) 
2 = Abnormal cervical cord signals 
50. PET – Whole body PET CT Scan 
0 = not done 
1 = normal 
2 = Abnormal (malignancy, 
infections, inflammation) 
3 = Abnormal Brain PET 
51. MRI2 – MRI Brain 
0 = not available 
1 = normal 
2 = Abnormal (old infarcts, 
nonsignificant small vessel disease) 
3 = Symmetrical Hyperintensities along 
cortico-spinal tracts 
52. Therapy – Therapeutic trial 
0 = symptomatic 
1 = Riluzole 
2 = Riluzole + Immunomodulation 
53. Response – Response to therapy 
0 = Present 
1 = No response 
2 = lost to follow up 
54. Outcome – Outcome at discharge 
0 = alive 
1 = died 
55. Followup1 & Followup2 – Follow up at 
3 months and at 6 months or later 
0 = No follow up 
1 = ALSFRS-R improving 
2 = ALSFRS-R static 
3 = ALSFRS-R worsening 
4 = died 
56. Bladder symptoms 
57. Myokymia 
0 = Absent; 1 = Present 
58. Extrapyramidal symptoms or signs 
0 = Absent 
1 = Present 
 
Name HospNo Adress Age Sex maritalstat Ioccpt education Htn Smoking IHD PVD RenalFail
Kakali Khanra 355738F W.B. 35 2 1 1 0.00 0 0 0 0 0
Annamma Varghese 285815f Kerela 65 2 1 0 4.00 0 0 0 0 0
Ranen Dutta 597029b W.B. 49 1 1 4 4.00 0 0 0 0 0
Yazmin 152226F Srilanka 56 2 1 4 4.00 1 0 0 0 0
Elizabeth Kunnel.SR 207100D Vellore 66 2 0 5 3.00 1 0 0 0 0
Saraswati Halder 499545D W.B. 49 2 1 0 3.00 0 0 0 0 0
Madhay Biswas 053832f W.B. 44 1 1 3 1.00 0 0 0 0 0
Radha Devi Lath 135690F Bihar 55 2 1 0 1.00 1 0 0 0 0
Imtiyaz Samim Mahmud 084538F W.B. 48 1 1 4 3.00 0 1 0 0 0
Arjun Prasad Yadav 029233f Bihar 45 1 1 5 3.00 1 0 0 0 0
Nilam Devi 210762F Jharkhand 49 2 1 0 1.00 0 0 0 0 0
Jibraiel Ansari 225584F Jharkhand 40 1 1 3 1.00 0 0 0 0 0
Sankar Kamila 205825F W.B. 51 1 1 3 1.00 0 0 0 0 0
Budheswar Kulley 201587F W.B. 35 1 1 1 0.00 0 0 0 0 0
Bhubaneswari Adhikari 286178F W.B. 49 2 1 0 2.00 0 0 0 0 0
Mukti Rani Sarkar 231994F W.B. 47 2 1 0 2.00 1 0 0 0 0
George Fenn T.B. 117703F Kerela 64 1 1 4 4.00 1 0 0 0 0
Subas Sardar 131357F W.B. 40 1 1 2 2.00 0 1 0 0 0
Bholanath jana 348509F W.B. 37 1 1 1 1.00 0 0 0 0 0
Kajaal Rani Barik 153137F W.B. 41 2 1 0 2.00 0 0 0 0 0
Dipali Dey Dutta 287904F W.B. 38 2 1 0 2.00 0 0 0 0 0
Kishor Ray 005026F Bihar 55 1 1 4 3.00 0 1 0 0 0
Md. Zahangir Alam Ali 906463D Bangladesh 47 1 1 4 3.00 0 1 0 0 0
Bala Anki Reddy B. 127433F A.P. 59 1 1 5 4.00 0 0 0 0 0
Tamilazakan B 205788F T.N. 42 1 1 4 4.00 0 0 0 0 0
Anil Kumar Gpta 315731F W.B. 53 1 1 4 4.00 0 1 0 0 0
Kochu Janaki M.E. 302602F Kerela 62 2 1 5 4.00 0 0 0 0 0
Jessy Thomas 285582F Kerela 48 2 1 5 4.00 0 0 0 0 0
Justice Abdul Gafoor 139520F Kerela 67 1 1 5 4.00 1 0 1 0 0
Bernice Gregory 382853F Kerela 60 2 1 0 4.00 0 0 0 0 0
Shyamapada Pal 391721F W.B. 53 1 1 4 4.00 0 0 0 0 0
Ravi Shankar 382388F Bihar 36 1 1 2 2.00 0 1 0 0 0
Raj Singh 182078F Assam 48 2 1 5 4.00 0 0 0 0 0
Palaniyandi 099530D T.N. 59 1 1 5 4.00 0 0 0 0 0
NativeMed Diabet Alcohol Obesity OP Vegetarian Toxin Hiphysical Familyhistory WeightLoss Neckheightratio CVS RS
0 0 0 0 1 0 0 1.00 0.00 1 1.0 0 0
1 0 0 1 0 0 0 0.00 0.00 2 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 1.00 0.00 1 1.0 0 0
0 1 0 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
1 0 0 0 1 0 1 1.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 0 0 1 0 0 1.00 0.00 1 1.0 0 0
1 0 0 0 1 0 0 1.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 1.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
1 1 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 1 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 1 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 1 0 0 0 0 1.00 0.00 2 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 1 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
0 0 0 0 0 1 0 0.00 0.00 2 1.0 0 0
1 0 0 0 0 0 1 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 1.00 0.00 2 1.0 1 0
0 0 0 0 0 0 0 0.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
0 0 1 0 0 0 0 0.00 0.00 1 1.0 0 0
0 0 0 0 0 0 0 1.00 0.00 1 1.0 0 0
1 0 0 0 0 0 0 0.00 0.00 2 1.0 0 0
ABD MMSE Olfact Vision Eyemov trig Facial vestc palate wasting Tone Nflx next
0 26 0 0 1 0 0 0 2 0 2 1 0
0 29 0 0 0 1 1 0 2 3 1 1 2
0 29 0 0 0 3 1 0 1 1 0 0 1
0 27 0 0 1 3 1 0 2 3 2 1 0
0 28 0 0 0 1 1 0 0 0 1 1 0
0 27 0 0 1 1 1 0 1 1 1 1 2
0 26 0 0 0 3 1 0 2 3 1 0 0
0 27 0 0 0 3 1 0 2 0 2 1 1
0 28 0 0 0 0 0 0 0 3 2 1 0
0 29 0 0 0 1 0 0 1 0 1 1 1
0 30 0 0 0 3 1 0 1 4 0 0 0
0 28 0 0 0 0 0 0 0 1 1 0 0
0 28 0 0 0 0 0 0 0 3 1 0 0
0 27 0 0 0 0 1 0 1 3 0 1 1
0 30 0 0 0 1 1 0 2 0 1 1 1
0 30 0 0 0 0 1 0 1 5 1 1 1
0 30 0 0 0 3 0 0 1 5 0 1 1
0 29 0 0 1 1 1 0 1 3 1 1 1
0 26 0 0 1 3 1 0 2 3 2 1 2
0 29 0 0 0 1 1 0 1 3 1 1 1
0 29 0 0 1 1 1 0 2 5 0 1 0
0 30 0 0 0 3 1 0 2 5 1 1 1
0 29 0 0 0 3 0 0 0 5 1 1 0
0 29 0 0 0 3 1 0 2 3 2 1 1
0 30 0 0 1 3 1 0 1 3 1 0 0
0 21 0 0 0 3 1 0 2 3 1 0 0
0 30 0 0 0 1 0 0 2 5 1 1 1
0 30 0 0 0 0 1 0 2 5 2 1 0
0 30 0 0 0 0 0 0 0 3 3 1 1
0 28 0 0 1 1 1 0 2 5 0 0 0
0 29 0 0 0 3 1 0 1 3 3 1 1
0 29 0 0 0 3 1 0 2 3 2 0 0
0 29 0 0 1 3 0 0 2 5 2 1 0
0 27 0 0 0 1 1 0 2 3 3 1 2
trunk ShabdR ShabdL ShaddR ShaddL ShflxR Shflx ShextR ShextL ElbflxR ElbflxL ElbextR ElbextL
1 5.00 5.00 5.00 5.00 5.00 5 4.00 4 5.00 5 4.00 4
1 4.00 2.00 4.00 2.00 4.00 2 4.00 2 4.00 2 4.00 2
1 4.00 5.00 4.00 5.00 4.00 5 4.00 5 4.00 5 4.00 5
1 4.00 4.00 4.00 3.00 4.00 4 4.00 3 4.00 4 4.00 4
1 5.00 5.00 5.00 5.00 5.00 5 5.00 5 5.00 5 5.00 5
1 3.00 3.00 3.00 3.00 3.00 3 3.00 3 4.00 4 4.00 4
1 4.00 4.00 4.00 4.00 4.00 4 4.00 4 4.00 4 4.00 4
1 3.00 4.00 4.00 3.00 3.00 3 4.00 3 3.00 3 2.00 2
1 4.00 4.00 4.00 4.00 3.00 3 4.00 4 4.00 4 3.00 3
1 2.00 2.00 2.00 2.00 3.00 3 2.00 2 4.00 4 3.00 3
0 5.00 5.00 5.00 5.00 5.00 5 5.00 5 5.00 5 5.00 5
1 3.00 3.00 3.00 3.00 4.00 3 4.00 3 3.00 4 3.00 4
1 4.00 3.00 4.00 3.00 4.00 3 4.00 3 4.00 3 4.00 3
1 2.00 2.00 2.00 2.00 2.00 2 2.00 2 3.00 3 3.00 3
1 4.00 3.00 4.00 3.00 4.00 3 4.00 3 4.00 4 4.00 4
1 5.00 5.00 5.00 5.00 5.00 5 5.00 5 5.00 5 5.00 5
1 4.00 4.00 4.00 4.00 4.00 4 4.00 4 3.00 3 4.00 4
1 4.00 3.00 4.00 3.00 3.00 3 3.00 3 4.00 3 4.00 3
1 4.00 4.00 4.00 4.00 4.00 4 4.00 4 4.00 4 3.00 3
1 4.00 4.00 5.00 5.00 5.00 5 4.00 4 4.00 4 3.00 3
1 4.00 4.00 4.00 4.00 4.00 4 4.00 4 4.00 4 4.00 4
1 1.00 5.00 1.00 5.00 1.00 5 1.00 5 3.00 5 3.00 5
1 2.00 4.00 3.00 5.00 2.00 5 2.00 5 2.00 5 3.00 5
1 2.00 2.00 2.00 2.00 2.00 2 2.00 2 2.00 3 3.00 3
0 4.00 4.00 4.00 4.00 4.00 3 3.00 3 5.00 3 3.00 3
0 4.00 5.00 4.00 4.00 4.00 3 3.00 3 4.00 4 3.00 3
1 5.00 5.00 5.00 5.00 5.00 5 5.00 5 5.00 5 5.00 5
1 4.00 4.00 4.00 4.00 4.00 4 3.00 3 4.00 4 4.00 4
1 2.00 2.00 2.00 2.00 2.00 3 2.00 2 3.00 3 4.00 4
1 5.00 5.00 5.00 5.00 5.00 5 5.00 5 5.00 5 5.00 5
1 4.00 4.00 3.00 3.00 4.00 4 3.00 3 4.00 4 3.00 3
0 3.00 3.00 4.00 4.00 3.00 3 3.00 3 5.00 5 5.00 5
1 4.00 4.00 4.00 4.00 4.00 4 4.00 4 5.00 5 4.00 4
1 1.00 1.00 2.00 2.00 2.00 2 2.00 2 2.00 2 3.00 3
WriflxR WriflxL WriextR WriextL HandgrpR HandgrpL HipflxR HipflxL HipextR HipextL KneeflxR KneeflxL KneeextR
5.00 5 4.00 4 1.00 1 4.00 4 5 5.00 4.00 4 5.00
4.00 2 4.00 2 1.00 1 4.00 2 3 2.00 3.00 3 4.00
4.00 5 4.00 5 1.00 1 4.00 5 4 5.00 4.00 5 4.00
3.00 3 4.00 3 1.00 1 5.00 5 5 5.00 4.00 4 5.00
5.00 5 5.00 5 1.00 1 4.00 5 4 5.00 3.00 5 4.00
4.00 4 4.00 4 1.00 1 5.00 5 5 5.00 5.00 5 5.00
4.00 4 4.00 4 1.00 1 4.00 4 4 4.00 4.00 4 4.00
2.00 3 2.00 2 1.00 1 3.00 4 4 3.00 3.00 3 3.00
4.00 4 3.00 3 1.00 1 4.00 4 4 4.00 4.00 4 4.00
3.00 3 1.00 1 1.00 1 4.00 4 4 4.00 4.00 4 4.00
5.00 5 5.00 5 1.00 1 5.00 5 5 5.00 5.00 5 5.00
3.00 2 2.00 2 1.00 1 4.00 4 4 4.00 5.00 5 5.00
3.00 2 3.00 2 1.00 1 4.00 4 4 4.00 4.00 4 4.00
2.00 2 2.00 2 1.00 1 4.00 4 4 4.00 4.00 4 3.00
5.00 3 4.00 4 0.00 1 3.00 3 3 3.00 4.00 4 4.00
4.00 4 4.00 4 1.00 1 5.00 5 5 5.00 5.00 5 5.00
4.00 4 4.00 4 1.00 1 5.00 5 5 5.00 5.00 5 5.00
4.00 3 4.00 3 1.00 1 3.00 4 3 4.00 3.00 4 3.00
4.00 4 3.00 3 1.00 1 4.00 4 4 4.00 4.00 4 4.00
4.00 4 3.00 3 1.00 1 4.00 4 4 4.00 3.00 3 4.00
4.00 4 4.00 4 0.00 0 5.00 5 5 5.00 5.00 5 5.00
2.00 4 2.00 4 1.00 0 5.00 5 5 5.00 5.00 5 5.00
3.00 5 2.00 5 1.00 0 5.00 5 5 5.00 5.00 5 5.00
3.00 3 2.00 2 1.00 1 2.00 3 2 3.00 3.00 3 3.00
3.00 3 2.00 2 1.00 1 4.00 4 2 2.00 4.00 4 4.00
4.00 3 3.00 3 1.00 1 5.00 5 4 4.00 4.00 4 5.00
5.00 5 5.00 5 0.00 0 4.00 4 4 4.00 4.00 4 4.00
4.00 4 4.00 4 1.00 1 4.00 4 4 4.00 3.00 3 4.00
4.00 4 3.00 3 1.00 1 2.00 1 2 2.00 2.00 2 3.00
5.00 5 5.00 5 0.00 0 5.00 5 5 5.00 5.00 5 5.00
3.00 3 2.00 2 1.00 1 3.00 2 4 3.00 3.00 3 4.00
5.00 5 5.00 5 0.00 0 3.00 3 4 4.00 4.00 4 4.00
4.00 4 3.00 4 1.00 1 4.00 4 4 4.00 4.00 4 4.00
3.00 3 1.00 1 1.00 1 4.00 3 3 3.00 2.00 2 3.00
KneeextL DorsR DorsL PlflxR PlflxL DTRs PlantarsR PlantarsL Supabd FascicsH FascicsE Sensory cerebellar
5 4.00 4 4.00 4 1 1 1 0 1.00 2.00 0 0
4 2.00 2 3.00 2 1 0 0 0 1.00 4.00 0 0
5 4.00 5 4.00 4 1 0 0 0 0.00 2.00 0 0
5 4.00 4 4.00 4 1 1 1 0 0.00 4.00 0 0
5 3.00 5 4.00 5 1 0 0 0 1.00 4.00 0 0
5 5.00 5 5.00 5 1 0 0 0 1.00 4.00 0 0
4 4.00 4 4.00 4 1 1 1 0 0.00 4.00 0 0
3 3.00 3 3.00 3 1 1 1 0 0.00 2.00 0 0
4 4.00 4 4.00 4 1 0 1 0 0.00 4.00 0 0
4 4.00 4 4.00 4 1 0 0 1 1.00 4.00 1 0
5 5.00 5 5.00 5 1 1 1 0 0.00 2.00 0 0
5 4.00 4 4.00 4 1 0 0 0 0.00 2.00 0 0
4 4.00 4 4.00 4 1 1 1 0 1.00 4.00 0 0
3 1.00 1 4.00 4 1 1 1 1 1.00 4.00 0 0
4 4.00 4 4.00 4 1 1 1 0 1.00 4.00 0 0
5 5.00 5 5.00 5 1 0 0 0 0.00 2.00 0 0
5 5.00 5 5.00 5 0 0 0 0 0.00 2.00 0 0
4 2.00 2 2.00 2 1 0 0 0 1.00 4.00 0 0
4 3.00 3 3.00 3 1 1 1 0 1.00 4.00 0 0
4 1.00 2 3.00 4 1 0 0 0 1.00 4.00 0 0
5 55.00 5 5.00 5 1 1 1 0 0.00 2.00 0 0
5 5.00 5 5.00 5 1 0 0 0 1.00 4.00 0 0
5 3.00 4 3.00 3 1 0 0 0 1.00 4.00 0 0
3 1.00 2 2.00 3 1 1 1 0 1.00 1.00 0 0
4 2.00 2 3.00 3 1 0 0 0 1.00 4.00 0 0
5 4.00 4 3.00 3 1 0 0 0 0.00 4.00 0 0
4 2.00 4 3.00 3 1 0 0 0 0.00 3.00 0 0
4 4.00 4 4.00 4 1 0 0 0 1.00 2.00 0 0
3 1.00 0 2.00 2 1 0 0 1 1.00 4.00 0 0
5 5.00 5 5.00 5 1 0 0 0 0.00 2.00 0 0
4 2.00 2 3.00 3 1 0 0 0 1.00 4.00 0 0
4 4.00 4 4.00 4 1 1 1 0 0.00 3.00 0 0
4 4.00 2 4.00 3 1 0 0 0 0.00 2.00 0 0
3 2.00 2 4.00 4 1 1 1 1 1.00 4.00 0 0
Romberg Gait rmcmp rmcmprox lmcmp lmcmprox rpcmp rpcmprox lpcmp lpcmprox rmdl lmdl rpdl
0 2 5.80 4.50 6.00 4.50 3.60 3.60 2.10 1.20 5.20 4.60 4.90
0 1 10.60 9.50 7.50 6.30 6.80 5.60 3.40 2.80 3.80 3.50 3.20
0 0 9.80 7.30 14.30 13.00 7.60 5.40 9.60 8.40 3.50 3.10 3.80
0 2 2.50 2.00 3.30 2.90 7.20 6.30 5.40 4.30 3.20 3.50 3.20
0 2 16.80 13.00 15.00 11.00 1.40 1.20 6.40 5.80 2.90 3.10 4.70
0 0 9.40 8.00 10.10 8.60 0.00 0.00 2.20 1.90 3.60 3.90 0.00
0 0 1.90 1.50 7.80 5.10 8.40 7.60 7.70 6.00 3.60 3.80 3.00
0 1 10.00 8.90 10.00 9.20 2.20 2.20 3.50 1.90 3.70 3.60 3.10
0 2 8.10 7.10 8.30 8.40 9.30 8.80 9.20 8.00 3.30 3.10 4.60
0 2 0.50 0.50 4.70 4.60 2.60 2.30 13.80 10.90 4.60 4.10 3.80
0 0 3.20 2.30 3.20 2.50 6.40 3.00 4.90 3.10 3.70 4.20 3.80
0 2 6.50 4.90 1.70 1.30 8.50 7.20 6.40 4.80 3.50 3.70 3.30
0 2 0.10 0.10 0.00 0.00 0.40 0.40 2.40 2.40 4.60 0.00 4.70
0 1 2.00 1.90 0.20 0.20 2.90 2.60 0.80 0.60 4.30 5.30 4.40
0 2 13.70 11.30 11.50 8.00 9.30 6.60 1.90 1.40 3.20 3.30 2.80
0 2 7.40 5.70 4.40 3.90 7.60 7.00 7.70 5.20 4.00 4.80 3.70
0 0 7.80 5.50 10.70 8.10 6.20 4.50 5.70 4.80 4.00 3.90 4.30
0 1 0.00 0.00 0.40 0.30 3.80 2.50 5.60 4.40 5.50 2.90 3.30
0 1 5.60 4.00 8.00 7.60 7.00 6.50 4.90 4.60 4.40 3.90 4.30
0 1 1.80 1.20 2.30 1.30 0.00 0.00 1.40 1.40 2.90 4.00 0.00
0 0 11.20 8.90 12.90 10.90 12.20 10.00 9.00 6.80 3.00 3.20 2.70
0 2 0.50 0.40 6.30 4.90 6.90 6.00 12.20 10.00 5.70 3.20 3.90
0 2 1.80 1.10 8.30 7.30 8.80 6.90 7.50 5.60 3.30 3.40 3.70
0 1 3.50 3.50 5.70 5.30 0.90 0.90 0.20 0.20 4.20 3.00 4.30
0 1 0.20 0.20 1.90 1.10 1.30 1.10 2.20 2.20 3.30 4.60 4.60
0 0 6.40 4.30 5.60 4.80 5.30 3.90 4.40 3.30 3.20 3.00 4.20
0 2 15.50 12.40 21.50 20.70 0.30 0.30 2.30 1.90 2.80 2.70 4.40
0 2 13.90 12.90 15.10 14.00 6.70 6.00 6.00 5.50 3.20 3.10 2.60
0 1 2.90 2.10 3.40 2.70 0.00 0.00 0.00 0.00 5.60 4.40 0.00
0 0 14.00 11.50 12.20 12.20 12.80 10.30 10.40 8.50 2.80 3.70 3.20
0 1 0.10 0.10 0.30 0.30 4.40 3.80 0.00 0.00 6.50 5.30 0.00
0 2 6.60 5.00 4.80 4.20 12.80 10.80 12.00 9.20 4.80 4.00 4.20
0 2 1.30 0.90 6.20 5.00 9.00 8.10 4.50 3.80 5.00 4.00 3.40
0 1 0.00 0.00 0.00 0.00 0.70 0.70 3.00 3.00 0.00 0.00 5.20
lpdl rmf lmf rpf lpf rmcv lmcv rpcv lpcv rmsnp lmsnp rsnp lssnp
5.30 27.80 28.20 46.90 43.00 46.00 49.00 41.00 54.00 96.00 87.00 34.00 22.00
4.80 24.30 23.90 41.90 43.10 55.00 57.00 44.00 40.00 31.00 28.00 36.00 37.00
3.50 28.90 24.90 41.80 48.40 53.00 56.00 54.00 55.00 46.00 35.00 45.00 41.00
3.30 27.90 25.40 46.60 43.40 57.00 59.00 51.00 51.00 9.00 70.00 22.00 21.00
4.30 25.10 24.60 51.50 50.60 56.00 62.00 47.00 45.00 40.00 46.00 23.00 27.00
4.80 29.70 30.40 0.00 51.50 55.00 50.00 0.00 42.00 32.00 42.00 22.00 20.00
3.40 29.40 29.70 41.70 41.70 57.00 60.00 47.00 53.00 46.00 50.00 64.00 61.00
3.30 25.80 25.40 42.40 47.30 63.00 54.00 58.00 52.00 25.00 20.00 16.00 20.00
5.10 27.80 25.20 46.60 46.80 61.00 58.00 43.00 49.00 28.00 24.00 33.00 29.00
3.30 0.00 29.10 56.50 52.60 76.00 55.00 58.00 47.00 67.00 70.00 58.00 63.00
3.10 22.30 31.30 40.30 40.10 44.00 48.00 50.00 51.00 35.00 21.00 24.00 28.00
3.30 21.10 25.60 48.00 43.90 59.00 60.00 51.00 53.00 49.00 52.00 37.00 32.00
4.70 0.00 0.00 0.00 46.00 38.00 0.00 41.00 49.00 41.00 35.00 22.00 27.00
5.10 33.00 0.00 55.70 52.20 40.00 48.00 45.00 44.00 30.00 25.00 27.00 23.00
4.40 23.30 26.10 41.40 42.70 65.00 52.00 69.00 64.00 90.00 84.00 50.00 59.00
4.20 28.30 27.70 44.70 45.30 55.00 62.00 52.00 54.00 35.00 53.00 26.00 24.00
4.70 29.80 28.00 54.70 52.70 56.00 53.00 48.00 51.00 21.00 20.00 19.00 18.00
3.60 0.00 0.00 43.40 51.90 0.00 64.00 58.00 58.00 32.00 29.00 15.00 10.00
4.40 31.70 21.60 41.70 40.90 79.00 67.00 58.00 64.00 27.00 33.00 31.00 32.00
4.80 26.60 26.50 0.00 0.00 50.00 68.00 0.00 43.00 66.00 44.00 30.00 21.00
2.70 24.70 24.20 38.50 38.90 45.00 58.00 45.00 49.00 88.00 75.00 52.00 77.00
3.50 32.90 27.10 46.20 43.90 51.00 57.00 47.00 45.00 42.00 46.00 21.00 24.00
3.70 0.00 29.30 48.20 49.30 51.00 49.00 49.00 46.00 41.00 35.00 26.00 20.00
4.80 30.90 31.40 0.00 0.00 51.00 48.00 41.00 30.00 19.00 27.00 14.00 13.00
4.20 0.00 0.00 49.60 51.30 70.00 53.00 47.00 46.00 36.00 37.00 27.00 22.00
4.10 29.00 31.80 51.70 52.00 57.00 57.00 45.00 45.00 23.00 22.00 10.00 6.00
3.10 29.80 23.90 52.90 55.00 59.00 58.00 34.00 40.00 36.00 46.00 50.00 46.00
2.90 23.90 24.50 43.50 44.10 58.00 62.00 49.00 53.00 22.00 25.00 28.00 23.00
0.00 33.70 33.90 0.00 0.00 48.00 54.00 0.00 0.00 23.00 24.00 20.00 17.00
3.60 25.50 24.50 44.50 46.30 55.00 68.00 45.00 49.00 35.00 33.00 24.00 31.00
5.00 0.00 0.00 51.10 0.00 47.00 44.00 46.00 0.00 54.00 57.00 23.00 36.00
4.40 38.30 30.00 44.50 49.60 51.00 57.00 51.00 51.00 96.00 43.00 31.00 59.00
3.80 31.00 28.00 46.00 49.00 60.00 57.00 48.00 48.00 41.00 37.00 27.00 58.00
2.80 0.00 0.00 0.00 49.30 0.00 0.00 56.00 48.00 20.00 30.00 19.00 23.00
rucmp rucmprox lucmp lucmprox rudl ludl ruf luf rucv lucv rusnp lusnp PhrenicL
8.90 5.70 9.90 5.60 3.60 3.80 27.40 27.80 54.00 53.00 65.00 73.00 7.20
8.30 6.00 6.10 6.10 2.50 2.70 24.10 24.00 51.00 77.00 28.00 30.00 0.00
4.50 2.90 18.40 16.70 3.50 2.70 30.50 26.30 59.00 62.00 31.00 22.00 0.00
4.00 2.40 2.40 1.90 2.60 2.90 26.50 27.80 58.00 52.00 23.00 35.00 7.20
14.80 12.10 11.10 10.50 2.10 2.10 26.50 26.80 65.00 64.00 35.00 30.00 8.20
10.60 9.70 8.50 6.40 2.80 3.50 28.80 28.20 56.00 57.00 25.00 25.00 7.80
4.80 2.50 5.70 3.50 2.70 2.90 27.40 31.50 63.00 63.00 25.00 36.00 0.00
9.50 8.70 10.30 9.30 3.00 2.10 26.40 23.90 78.00 84.00 20.00 24.00 0.00
6.50 5.90 8.10 6.30 2.80 2.70 27.60 26.70 64.00 58.00 32.00 34.00 0.00
2.50 2.40 3.10 2.10 2.60 3.50 31.40 30.20 50.00 57.00 32.00 27.00 4.40
10.80 7.20 9.00 7.00 2.90 3.80 25.40 25.90 71.00 60.00 22.00 31.00 0.00
1.60 1.40 1.60 1.40 3.40 3.50 29.40 29.40 63.00 59.00 31.00 25.00 0.00
9.20 8.80 0.40 0.40 2.90 5.40 29.40 0.00 60.00 47.00 63.00 67.00 0.00
1.30 1.10 1.60 1.40 4.10 4.50 29.80 30.20 55.00 55.00 70.00 67.00 0.00
15.10 12.00 8.80 7.10 2.20 2.90 22.40 27.50 71.00 53.00 40.00 38.00 0.00
10.30 8.40 7.10 5.40 2.90 2.80 27.50 26.20 63.00 59.00 38.00 32.00 0.00
12.50 11.20 10.80 9.80 3.00 3.50 30.30 30.30 55.00 60.00 19.00 17.00 8.40
3.10 2.50 4.30 2.10 2.90 2.80 30.20 0.00 61.00 58.00 27.00 18.00 7.10
1.20 1.20 0.80 0.70 3.10 3.80 0.00 0.00 62.00 63.00 22.00 21.00 0.00
8.30 7.10 5.30 3.90 2.80 3.00 29.10 28.30 64.00 60.00 36.00 49.00 7.00
12.00 10.40 12.00 8.50 2.80 2.70 24.10 24.70 67.00 60.00 41.00 45.00 7.00
0.00 0.00 7.40 6.80 0.00 2.70 0.00 27.20 0.00 65.00 29.00 25.00 7.20
3.90 3.10 13.60 11.90 3.00 2.90 33.00 31.00 55.00 63.00 21.00 21.00 0.00
3.60 2.90 8.90 7.50 3.20 3.10 31.50 29.30 48.00 58.00 14.00 24.00 9.00
0.80 0.80 3.00 1.60 3.20 2.70 0.00 0.00 77.00 60.00 25.00 42.00 0.00
9.50 8.70 4.70 3.50 3.10 3.20 29.50 32.40 56.00 62.00 15.00 14.00 0.00
11.50 8.90 12.30 10.10 2.50 2.40 24.00 26.00 57.00 63.00 65.00 58.00 0.00
14.00 13.00 12.70 10.70 2.10 2.20 24.50 23.00 63.00 72.00 25.00 27.00 0.00
4.40 3.10 6.80 4.70 3.90 3.70 35.60 31.90 40.00 42.00 18.00 21.00 0.00
13.30 11.10 13.70 11.80 2.60 2.60 27.30 28.50 63.00 69.00 23.00 29.00 0.00
2.70 1.60 5.40 3.70 4.70 3.60 0.00 34.00 42.00 52.00 23.00 25.00 0.00
4.90 2.90 6.10 4.60 3.30 3.30 28.80 37.70 60.00 60.00 42.00 40.00 0.00
4.90 3.70 7.00 5.60 2.90 2.60 30.00 46.00 63.00 59.00 27.00 27.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 21.00 25.00 8.70
PhrenicA Proxconduc Condbloc AcDenerBulb AcDenerCer AcDenerTho AcDenerLS ChrDenerBulb ChrDenerCer ChrDenerThoChrDenerLS Elesco Awaji
4.30 0.00 3.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.80 0.00 3.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.70 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
2.90 0.00 3.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 1.00 0.00 1.00 1.00 1.00
0.00 1.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 0.00 1.00 2.00 1.00
0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
2.40 0.00 0.00 1.00 1.00 0.00 1.00 1.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 2.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
1.10 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.60 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00
0.70 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
1.20 0.00 0.00 1.00 1.00 0.00 0.00 0.00 1.00 0.00 1.00 1.00 0.00
0.50 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
1.00 0.00 0.00 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 2.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 0.00 1.00 1.00 0.00 0.00 1.00 0.00 1.00 1.00 1.00
0.00 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00 0.00
0.00 0.00 3.00 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00 1.00 0.00 0.00 0.00 1.00 0.00 1.00 1.00 0.00
0.00 0.00 3.00 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 0.00
1.80 0.00 2.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00
Spirometry Barium CSFC CSFP Immune Toxscrn PEG MRI1 MRI2 PET Therapy Response duration
1.00 1.00 1.00 2.00 2.00 2.00 0.00 1.00 3.00 0.00 2.00 2.00 12.00
1.00 2.00 1.00 1.00 1.00 0.00 2.00 1.00 2.00 1.00 1.00 1.00 12.00
1.00 0.00 0.00 0.00 0.00 1.00 1.00 1.00 2.00 0.00 2.00 2.00 24.00
1.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 3.00 2.00 2.00 1.00 15.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 2.00 1.00 0.00 1.00 6.00
3.00 2.00 1.00 1.00 1.00 1.00 2.00 1.00 1.00 1.00 2.00 1.00 48.00
0.00 0.00 1.00 1.00 0.00 2.00 0.00 1.00 1.00 0.00 1.00 1.00 8.00
1.00 1.00 0.00 0.00 1.00 0.00 0.00 1.00 2.00 2.00 2.00 1.00 24.00
4.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 3.00 2.00 1.00 1.00 12.00
1.00 3.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 0.00 2.00 1.00 24.00
4.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 2.00 1.00 2.00 12.00
4.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.00 1.00 1.00 24.00
4.00 1.00 1.00 2.00 1.00 1.00 0.00 1.00 1.00 0.00 1.00 1.00 60.00
1.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 3.00 1.00 2.00 1.00 12.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 6.00
0.00 1.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.00 1.00 1.00 12.00
0.00 1.00 1.00 2.00 1.00 0.00 0.00 1.00 1.00 2.00 2.00 1.00 12.00
3.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 3.00 0.00 1.00 2.00 8.00
1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 3.00 0.00 2.00 1.00 36.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.00 2.00 1.00 24.00
1.00 3.00 1.00 1.00 1.00 0.00 0.00 1.00 1.00 0.00 2.00 1.00 9.00
1.00 1.00 0.00 0.00 1.00 0.00 0.00 1.00 1.00 0.00 2.00 2.00 36.00
0.00 0.00 1.00 2.00 1.00 0.00 0.00 1.00 1.00 1.00 2.00 1.00 14.00
1.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 0.00 1.00 1.00 18.00
1.00 3.00 1.00 2.00 1.00 1.00 0.00 1.00 3.00 1.00 2.00 2.00 16.00
1.00 3.00 1.00 1.00 1.00 1.00 0.00 1.00 2.00 2.00 2.00 1.00 36.00
0.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 1.00 2.00 24.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 2.00 1.00 1.00 0.00 72.00
1.00 0.00 0.00 0.00 1.00 1.00 0.00 1.00 1.00 0.00 2.00 2.00 8.00
1.00 2.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 2.00 2.00 1.00 4.00
1.00 0.00 1.00 2.00 1.00 1.00 0.00 1.00 1.00 0.00 2.00 2.00 18.00
0.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 3.00 0.00 2.00 1.00 6.00
1.00 0.00 1.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 2.00 1.00 15.00
3.00 2.00 0.00 0.00 2.00 1.00 1.00 1.00 1.00 0.00 2.00 0.00 84.00
Onset Progression1 Progression2 ALSFRS Outcome Followup1 Followup2 CognitionP CognitionN CognitionA CognitionACE CognitionF RTCorFA
2.00 1.00 2.00 32.00 0.00 3.00 0.00 1.00 1.00 2.00 1.00 2.00 0.53
1.00 0.00 2.00 35.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.47
0.00 1.00 2.00 29.00 0.00 0.00 0.00 1.00 1.00 2.00 1.00 1.00 0.50
1.00 0.00 3.00 38.00 0.00 3.00 3.00 1.00 1.00 1.00 1.00 1.00 0.56
2.00 3.00 1.00 32.00 0.00 0.00 0.00 1.00 1.00 2.00 2.00 3.00 0.51
0.00 2.00 3.00 29.00 0.00 3.00 3.00 1.00 1.00 2.00 2.00 3.00 0.50
1.00 0.00 2.00 40.00 0.00 3.00 0.00 1.00 2.00 2.00 1.00 1.00 0.59
1.00 0.00 2.00 40.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.53
1.00 0.00 2.00 43.00 0.00 0.00 3.00 1.00 2.00 2.00 2.00 1.00 0.53
1.00 0.00 1.00 33.00 0.00 3.00 3.00 1.00 1.00 1.00 1.00 1.00 0.56
0.00 2.00 2.00 44.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.51
1.00 0.00 3.00 42.00 0.00 0.00 0.00 1.00 1.00 2.00 2.00 1.00 0.45
1.00 0.00 3.00 36.00 0.00 0.00 0.00 1.00 1.00 2.00 1.00 1.00 0.43
1.00 0.00 1.00 33.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.49
1.00 0.00 2.00 42.00 0.00 3.00 0.00 1.00 1.00 1.00 1.00 1.00 0.60
0.00 2.00 2.00 42.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.51
0.00 2.00 2.00 42.00 0.00 0.00 0.00 1.00 1.00 2.00 2.00 1.00 0.53
1.00 0.00 2.00 33.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.48
2.00 1.00 1.00 29.00 0.00 3.00 3.00 1.00 2.00 2.00 2.00 1.00 0.39
2.00 1.00 1.00 34.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.41
0.00 2.00 2.00 38.00 0.00 3.00 0.00 1.00 1.00 1.00 1.00 1.00 0.52
1.00 0.00 3.00 36.00 0.00 0.00 0.00 1.00 1.00 2.00 2.00 1.00 0.48
1.00 0.00 2.00 42.00 0.00 3.00 3.00 1.00 1.00 1.00 1.00 1.00 0.51
2.00 1.00 2.00 35.00 0.00 2.00 3.00 1.00 1.00 2.00 1.00 1.00 0.45
2.00 1.00 1.00 28.00 0.00 3.00 3.00 1.00 1.00 1.00 1.00 1.00 0.50
1.00 0.00 3.00 44.00 0.00 3.00 0.00 2.00 2.00 2.00 2.00 4.00 0.52
2.00 1.00 2.00 44.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.47
0.00 4.00 3.00 42.00 0.00 0.00 2.00 1.00 1.00 1.00 1.00 1.00 0.37
2.00 1.00 1.00 29.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 1.00 0.51
0.00 2.00 2.00 37.00 0.00 2.00 0.00 1.00 1.00 2.00 2.00 1.00 0.51
2.00 1.00 1.00 29.00 0.00 2.00 3.00 1.00 1.00 1.00 1.00 1.00 0.48
2.00 1.00 1.00 34.00 0.00 2.00 3.00 1.00 1.00 2.00 1.00 1.00 0.50
2.00 1.00 2.00 35.00 0.00 3.00 3.00 1.00 1.00 1.00 1.00 1.00 0.43
1.00 0.00 1.00 14.00 0.00 2.00 3.00 1.00 1.00 2.00 1.00 1.00 0.56
LTCorFA RTPLICFA LTPLICFA RPenFA LPenFA RPyrFA LPyrFA RTCorMD LTCorMD RTPLICMD LTPLICMD RPenMD LPenMD
0.57 0.69 0.65 0.71 0.77 0.55 0.54
0.52 0.72 0.58 0.66 0.68 0.44 0.44 1.06 1.10 0.81 0.78 1.05 0.82
0.51 0.56 0.57 0.65 0.66 0.50 0.38 0.86 0.77 0.89 0.86 0.90 1.01
0.55 0.56 0.59 0.63 0.61 0.47 0.45 0.83 0.86 0.94 0.82 0.81 1.00
0.31 0.70 0.65 0.62 0.73 0.54 0.54
0.60 0.64 0.67 0.57 0.82 0.48 0.54 0.98 0.93 0.81 0.78 0.88 0.96
0.49 0.62 0.64 0.67 0.75 0.49 0.46 0.88 0.84 0.95 0.84 0.83 0.92
0.49 0.62 0.58 0.53 0.77 0.52 0.51 0.83 0.89 0.92 0.79 0.97 0.85
0.51 0.58 0.59 0.61 0.62 0.41 0.42 1.00 0.83 0.96 0.83 1.00 0.93
0.54 0.58 0.62 0.68 0.74 0.53 0.51 0.94 0.90 0.85 0.89 0.88 0.82
0.47 0.56 0.66 0.65 0.64 0.48 0.49 0.85 0.94 0.87 1.02 0.85 1.16
0.47 0.58 0.63 0.63 0.72 0.43 0.51 1.02 1.05 1.01 1.00 1.05 0.95
0.51 0.65 0.67 0.66 0.62 0.45 0.46 0.91 0.89 1.01 1.06 0.85 0.99
0.47 0.63 0.63 0.65 0.74 0.47 0.49 0.80 0.81 1.09 1.00 0.82 0.82
0.54 0.75 0.68 0.67 0.74 0.50 0.42 0.96 0.77 0.94 0.86 0.92 0.92
0.47 0.58 0.61 0.61 0.68 0.49 0.42 0.91 0.91 1.05 1.01 0.86 0.86
0.57 0.69 0.65 0.69 0.75 0.50 0.50 0.90 0.76 0.90 0.84 0.84 0.94
0.46 0.64 0.66 0.62 0.62 0.55 0.51 0.86 0.90 0.88 0.78 0.89 0.90
0.31 0.62 0.58 0.63 0.60 0.48 0.44
0.38 0.62 0.62 0.68 0.73 0.55 0.58
0.36 0.63 0.65 0.60 0.68 0.48 0.56
0.56 0.61 0.63 0.63 0.73 0.45 0.42 0.79 0.97 0.87 0.87 1.03 0.86
0.55 0.69 0.65 0.71 0.67 0.49 0.52
0.53 0.67 0.62 0.66 0.73 0.48 0.51 0.95 0.85 0.84 1.00 0.86 0.72
0.52 0.68 0.62 0.67 0.66 0.50 0.54 0.88 0.92 0.98 0.92 0.86 0.92
0.49 0.67 0.65 0.65 0.67 0.43 0.52 0.86 0.89 0.86 0.87 0.85 0.83
0.40 0.68 0.71 0.71 0.72 0.63 0.56
0.33 0.68 0.63 0.58 0.63 0.51 0.53
0.50 0.65 0.67 0.70 0.66 0.55 0.49 0.94 0.84 0.79 0.96 1.01 0.82
0.46 0.67 0.65 0.73 0.77 0.48 0.49
0.55 0.67 0.68 0.75 0.73 0.59 0.58
0.55 0.51 0.62 0.69 0.69 0.41 0.47
0.39 0.72 0.63 0.75 0.72 0.62 0.63
0.58 0.68 0.65 0.62 0.75 0.39 0.48 0.84 0.83 0.91 0.87 0.86 0.95
RPyrMD LPyrMD
0.78 0.82
0.98 1.01
0.89 0.89
0.81 0.88
0.95 0.74
0.86 0.93
0.90 0.90
1.00 0.97
0.98 0.93
0.68 0.94
1.10 0.86
1.03 0.99
1.08 0.83
1.10 1.00
1.00 0.97
0.93 0.90
1.03 0.76
0.87 0.72
1.03 0.84
0.70 0.93
0.75 0.74
1.10 0.93
